General Principles
==================

The criteria of the German Consortium for Hereditary Breast and Ovarian Cancer ( <http://www.konsortium-familiaerer-brustkrebs.de/> ) for the classification of germline sequence variants in risk genes for hereditary breast and ovarian cancer were developed and compiled by the members of the panel of experts on variant evaluation (VUS Task Force) from the German Consortium for Hereditary Breast and Ovarian Cancer listed above. The task of this panel of experts is to specify binding criteria for the German Consortium for Hereditary Breast and Ovarian Cancer to evaluate variants and verify the classification of variants to ensure that variants are uniformly evaluated by the Consortium. The present criteria are based on the IARC [^1^](#FN11100909-1){ref-type="fn"} 5-class system for high-risk genes [^2^](#FN11100909-2){ref-type="fn"} which is based on the guidelines issued by the ENIGMA [^3^](#FN11100909-3){ref-type="fn"} Consortium (ENIGMA *BRCA1/2* Classification Criteria, Version 2.5.1, June 2017), as well as the ACMG [^4^](#FN11100909-4){ref-type="fn"} and ACGS [^5^](#FN11100909-5){ref-type="fn"} guidelines. Using this 5-class system, germline sequence variants are evaluated in terms of their relevance for a loss of function of the coded protein (Class1: neutral, Class2: likely neutral, Class3: uncertain evidence/no reliable evaluation, Class4: likely relevant loss of function, Class5: relevant loss of function; level of significance, see [@R11100909-4] ). For high-penetrance genes (such as *BRCA1, BRCA2* ) for which a clinical correlation (pathogenicity) with loss of function has been described, the functional classification yields a pathogenicity evaluation based on the IARC 5-class system (ranging from Class1: not pathogenic to Class5: pathogenic), as outlined in Appendix A 2, [Table 1](#TB11100909-1){ref-type="table"} . The advantage of such a structured approach is that it starts by checking for defined criteria which can be used for a quick and unambiguous classification, and the extensive data and literature search is only carried out afterwards (see Appendix A 2, [Table 2](#TB11100909-2){ref-type="table"} : Relevant literature and databases, and A 3, [Fig. 1](#FI11100909-1){ref-type="fig"} : Evaluation criteria flow chart). As regards the classification of sequence variants of the genes *ATM, BRCA1, BRCA2, BRIP1, CDH1, CHEK2, PALB2, RAD51C, RAD51D* and *TP53* , all of them so-called "core genes" according to the TruRisk panel (version 1/2018, see the homepage of the German Consortium: <http://www.konsortium-familiaerer-brustkrebs.de/> ), the specific features of the individual genes listed in Appendix A 5 must be taken into account. Moderate/low-penetrance genes are only evaluated in terms of their functionality (in these cases: loss of function should not be equated with "pathogenicity"). Even variants of high-risk genes may only be associated with an intermediate risk [@R11100909-5] ,  [@R11100909-6] .

###### 

**Table 1**  IARC 5-tiered classification system with accompanying recommendations for family management ^a^ (excerpt from <https://enigmaconsortium.org/wp-content/uploads/2018/10/ENIGMA_Rules_2017-06-29-v2.5.1.pdf> ).

  Class                                                         Quantitative measure: probability of pathogenicity   Predictive testing of at-risk relatives   Surveillance of at-risk relatives                                                                                       Research testing of relatives
  ------------------------------------------------------------- ---------------------------------------------------- ----------------------------------------- ----------------------------------------------------------------------------------------------------------------------- -------------------------------
  5: Pathogenic                                                 \> 0.99                                              Yes                                       Full high-risk guidelines for variant carriers                                                                          Not indicated
  4: Likely pathogenic                                          0.95 -- 0.99                                         Yes ^b^                                   Full high-risk guidelines for variant carriers                                                                          Yes
  3: Uncertain                                                  0.05 -- 0.949                                        No ^b^                                    Based on family history & other risk factors                                                                            Yes
  2: Likely not pathogenic or of little clinical significance   0.001 -- 0.049                                       No ^b^                                    Based on family history & other risk factors -- treat as "no *BRCA1/2* pathogenic variant detected" for this disorder   Yes
  1: Not pathogenic or of no clinical significance              \< 0.001                                             No ^b^                                    Based on family history & other risk factors -- treat as "no *BRCA1/2* pathogenic variant detected" for this disorder   Not indicated

###### 

**Table 2**  Relevant literature and databases available for evaluation.

  Database                                                                                                                                                                                              URL
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------
  1000Genomes                                                                                                                                                                                           <http://www.1000genomes.org/>
  ARUP *(BRCA1)*                                                                                                                                                                                        <http://arup.utah.edu/database/BRCA/Variants/BRCA1>
  ARUP *(BRCA2)*                                                                                                                                                                                        <http://arup.utah.edu/database/BRCA/Variants/BRCA2>
  BIC ( **B** reast Cancer **I** nformation **C** ore)                                                                                                                                                  <http://research.nhgri.nih.gov/bic/>
  BRCA1 CIRCOS (via BIC, or **Caution:** specify BIC nomenclature!)                                                                                                                                     <https://research.nhgri.nih.gov/projects/bic/circos/search.shtml>
  BRCA Exchange                                                                                                                                                                                         <http://brcaexchange.org>
  ClinVar (ClinGen)                                                                                                                                                                                     <https://www.ncbi.nlm.nih.gov/clinvar/>
  Database of Functional Classifications of *BRCA1* Variants based on Saturation Genome Editing [@R11100909-15] ,  [@R11100909-16]                                                                      <https://sge.gs.washington.edu/BRCA1/>
  dbSNP                                                                                                                                                                                                 <https://www.ncbi.nlm.nih.gov/snp>
  EVS/ESP                                                                                                                                                                                               <http://evs.gs.washington.edu/EVS/>
  Exome Aggregation Consortium ExAC Browser                                                                                                                                                             <http://exac.broadinstitute.org/>
  exUV-LOVD (multifactorial analysis of reclassified *BRCA1/2* variants)                                                                                                                                <http://hci-exlovd.hci.utah.edu/home.php>
  FLOSSIES ( **F** abulous **L** adies **O** ver **S** eventy: germline variants for 27 breast cancer-relevant genes in approx. 10 000 women aged \> 70 years, who have not developed cancer to date)   <https://whi.color.com/>
  Genome Aggregation Database GnomAD                                                                                                                                                                    <http://gnomad.broadinstitute.org/>
  Google Scholar                                                                                                                                                                                        <http://scholar.google.de/>
  HGMD Professional (registration required)                                                                                                                                                             <https://portal.biobase-international.com/>
  IARC *TP53* database                                                                                                                                                                                  <http://p53.iarc.fr/>
  InSiGHT Consortium (classification database)                                                                                                                                                          <http://www.insight-database.org/classifications/>
  KAVIAR (Known VARiants, genomic)                                                                                                                                                                      <http://db.systemsbiology.net/kaviar/cgi-pub/Kaviar.pl>
  LOVD (Leiden Open Variation Database, general)                                                                                                                                                        <http://www.lovd.nl/3.0/home>
  LOVD database, *ATM*                                                                                                                                                                                  <https://databases.lovd.nl/shared/genes/ATM>
  LOVD database, *BRCA1*                                                                                                                                                                                <https://databases.lovd.nl/shared/genes/BRCA1>
  LOVD database, *BRCA2*                                                                                                                                                                                <https://databases.lovd.nl/shared/genes/BRCA2>
  LOVD database, *BRIP1*                                                                                                                                                                                <http://databases.lovd.nl/shared/genes/BRIP1>
  LOVD database, *CDH1*                                                                                                                                                                                 <http://databases.lovd.nl/shared/genes/CDH1>
  LOVD database, *CHEK2*                                                                                                                                                                                <https://databases.lovd.nl/shared/genes/CHEK2>
  LOVD database, *PALB2*                                                                                                                                                                                <http://databases.lovd.nl/shared/genes/PALB2>
  LOVD database, *RAD51C*                                                                                                                                                                               <https://databases.lovd.nl/shared/genes/RAD51C>
  LOVD database, *RAD51D*                                                                                                                                                                               <https://databases.lovd.nl/shared/genes/RAD51D>
  LOVD database, *TP53*                                                                                                                                                                                 <https://databases.lovd.nl/shared/genes/TP53>
  PubMed                                                                                                                                                                                                <http://www.ncbi.nlm.nih.gov/pubmed/>
  *TP53* , PHANTM (genotype/phenotype correlation)                                                                                                                                                      <http://mutantp53.broadinstitute.org/heatMap/login>
  UMD ( **U** niv. **M** utation **D** atabase, LSDB: Locus Specific Databases)                                                                                                                         <http://www.umd.be/>
  UMD/BRCAshare- *BRCA1* (registration required)                                                                                                                                                        <http://www.umd.be/BRCA1> /
  UMD/BRCAshare- *BRCA2* (registration required)                                                                                                                                                        <http://www.umd.be/BRCA2/>
  UMD *TP53*                                                                                                                                                                                            <http://p53.fr/tp53-database>
  VarSeak                                                                                                                                                                                               <https://varseak.bio/>
  VarSome (automated ACMG classification)                                                                                                                                                               <https://varsome.com/>

![ VUS evaluation criteria 1.1.](10-1055-a-1110-0909-igf01){#FI11100909-1}

Criteria for the Interpretation of mRNA Analyses
================================================

The criteria of the German Consortium for Hereditary Breast and Ovarian Cancer for the evaluation of sequence variants with subsequent mRNA analysis are based on the guidelines of the ENIGMA Consortium (see also [@R11100909-7] ). The respective threshold values of potential splice variants for an empirical predictive prognosis based on three commonly used predictive programmes are given in Appendix A 1. Appendix A 4 ( [Fig. 2](#FI11100909-2){ref-type="fig"} ) gives a schematic representation of the areas considered by the VUS Task Force when evaluating the splice variants. mRNA analysis is carried out using fresh blood samples, cultured lymphocytes, cultured lymphoblastoid cell lines, etc. and compared in parallel with at least 5 controls of the same type of material. A sequence variant is described as pathogenic if it has the following effect on mRNA transcription: one or more aberrant transcripts of the variant allele are detected, which lead to a stop codon or an in-frame deletion and result in the destruction of known functional domains. Sequencing of the full-length transcript of the variant allele or the presence of an intronic variant of a cis-acting polymorphism is considered sufficient (evidence of monoallelic expression) to determine the transcript amount (using semi-quantitative or quantitative methods). Variants which show a transcript pattern comparable to the mean value of controls are rated as neutral/not pathogenic due to the lack of aberrant mRNA. As regards the cDNA primer design, the physiological splice variants/naturally occurring isoforms must also be taken into account (see [@R11100909-8] ,  [@R11100909-9] ).

![ Classification of variants which can affect splicing.](10-1055-a-1110-0909-igf02){#FI11100909-2}

**Caution:** Certain *BRCA1* and *BRCA2* variants which are ± 1, 2 bp from the exon border and which are predicted or proven to lead to at least 20 -- 30% naturally occurring in-frame RNA isoforms per allele could presumably result in some residual protein activity (see [@R11100909-9] ,  [@R11100909-10] ,  [@R11100909-11] ,  [@R11100909-12] ) and are therefore classified as VUS Class3, unless there is evidence to the contrary (see Overview, Appendix 5, [Table 5](#TB11100909-5){ref-type="table"} )

###### 

**Table 5**  Excerpt from <https://enigmaconsortium.org/wp-content/uploads/2018/10/ENIGMA_Rules_2017-06-29-v2.5.1.pdf> .

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Table 6: *BRCA1* and *BRCA2* exon boundary variants predicted or known to lead to naturally occurring in-frame RNA isoforms that may rescue gene functionality. *Variants at these positions should be considered Class3 Uncertain unless proven otherwise.\**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- --------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  *BRCA1*                                                                                                                                                                                                                                                          Δ8p                   c.442-1 (IVS7-1)\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              *BRCA1* exon 8 acceptor site is an experimentally validated tandem acceptor site (NAGNAG) subject to alternative splicing (Colombo et al., 2014). c.442-1,-2 variants are predicted to inactivate the 5′ acceptor site, but not the 3′ acceptor site, thus producing Δ8p transcripts.
                                                                                                                                                                                                                                                                                         c.442-2 (IVS7-2)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               

  Δ9,10                                                                                                                                                                                                                                                            c.548-1 (IVS8-1)\     Carriers of variants at these positions are predicted to produce normal (or increased) levels of *BRCA1* Δ(9,10), a major in-frame alternative splicing event (Colombo et al., 2014).\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         
                                                                                                                                                                                                                                                                   c.548-2 (IVS8-2)\     The *BRCA1* variant c.594-2A\>C (shown from ENIGMA research to co-occur in cis with c.641A\>G), has been reported to demonstrate clinical characteristics inconsistent with a high risk of cancer expected for a pathogenic *BRCA1* variant (Rosenthal et al., 2015). The haplotype of c.\[594-2A\>C; 641A\>G\] has been shown from mRNA analysis in human samples to produce high levels of Δ10 transcripts (70% of the overall expression, and **has been designated as Class1 Not Pathogenic** by the ENIGMA Consortium using multifactorial likelihood analysis that includes genetic (segregation, case-control analysis) and pathology data (de la Hoya et al., 2016).   
                                                                                                                                                                                                                                                                   c.593 to non-G\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      
                                                                                                                                                                                                                                                                   c.593+1 (IVS9+1)\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    
                                                                                                                                                                                                                                                                   c.593+2 (IVS9+2)\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    
                                                                                                                                                                                                                                                                   c.594-1 (IVS9-1)\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    
                                                                                                                                                                                                                                                                   c.594-2 (IVS9-2)\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    
                                                                                                                                                                                                                                                                   c.670 to non-G\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      
                                                                                                                                                                                                                                                                   c.670+1 (IVS10+1)\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   
                                                                                                                                                                                                                                                                   c.670+2 (IVS10+2)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    

  Δ11q, Δ11                                                                                                                                                                                                                                                        c.4096 to non-G\      Data collected by the ENIGMA consortium demonstrates that the *BRCA1* c.4096+1G\>A variant, proven to result in the production of naturally occurring in-frame transcripts Δ11q (Bonatti et al., 2006) and also Δ11 (Radice, unpublished data), may not exhibit the clinical characteristics of a standard high-risk pathogenic *BRCA1* variant (Spurdle, unpublished data).                                                                                                                                                                                                                                                                                                   
                                                                                                                                                                                                                                                                   c.4096+1 (IVS11+1)\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  
                                                                                                                                                                                                                                                                   c.4097+2 (IVS11+2)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   

  Δ13p                                                                                                                                                                                                                                                             c.4186-1 (IVS12-1)\   *BRCA1* exon 13 acceptor site is an experimentally validated tandem acceptor site (NAGNAG) subject to alternative splicing (Colombo et al., 2014). c.4186-1,-2 variants are predicted to inactivate the 5′ acceptor site, but not the 3′ acceptor site, thus producing Δ13p transcripts.                                                                                                                                                                                                                                                                                                                                                                                       
                                                                                                                                                                                                                                                                   c.4186-2 (IVS12-2)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   

  Δ14p                                                                                                                                                                                                                                                             c.4358-1 (IVS13-1)\   *BRCA1* exon 14 acceptor site is an experimentally validated tandem acceptor site (NAGNAG) subject to alternative splicing (Colombo et al., 2014). c.4358-1,-2 variants are predicted to inactivate the 5′ acceptor site, but not the 3′ acceptor site, thus producing Δ14p transcripts.                                                                                                                                                                                                                                                                                                                                                                                       
                                                                                                                                                                                                                                                                   c.4358-2 (IVS13-2)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   

  *BRCA2*                                                                                                                                                                                                                                                          Δ12                   c.6842-1 (IVS11-1)\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            Carriers of these variants are predicted to produce exon 12 skipping. BRCA2 Δ12 is a naturally occurring in-frame splicing event (Fackenthal et al., 2016). BRCA2 exon 12 is functionally redundant (Li et al., 2009).
                                                                                                                                                                                                                                                                                         c.6842-2 (IVS11-2)\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            
                                                                                                                                                                                                                                                                                         c.6937 to non-G\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               
                                                                                                                                                                                                                                                                                         c.6937+1 (IVS12+1)\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            
                                                                                                                                                                                                                                                                                         c.6937+2 (IVS12+2)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Approach of the VUS Task Force
------------------------------

The Consortium recommends routinely testing for 10 genes which are known (as per 8/19) to be associated with breast and/or ovarian cancer: *ATM, BRCA1, BRCA2, BRIP1, CDH1, CHEK2, PALB2, RAD51C, RAD51D* and *TP53* ( <http://www.konsortium-familiaerer-brustkrebs.de/> ).

The Consortiumʼs panel of experts (VUS Task Force) holds monthly telephone conferences and, if necessary, meetings to reach a consensus on the classification of newly reported sequence variants, discuss any new evidence available for the re-evaluation of already known variants, and evaluate variants of unclear significance. In the event of a re-evaluation, the central database of the Consortium will inform all centres about the reclassification (recall system).

**It should be expressly noted that new information can lead to changes in the classification of variants and that these classifications are regularly reviewed by the panel of experts. Similarly, new findings can lead to changes in the list of core genes for which the German Consortium for Hereditary Breast and Ovarian Cancer recommends that patients are tested. All such changes along with the inclusion of new findings into the classification are published on the homepage of the German Consortium for Hereditary Breast and Ovarian Cancer (** <http://www.konsortium-familiaerer-brustkrebs.de/> **).**

Classification of Sequence Variants According to Their Functional Relevance
===========================================================================

**1.   Class1 (functionally irrelevant/no loss of function) if one of the following criteria is met:**

1.1   Allele frequency of variants in large population groups (e.g. Caucasians, Africans, or Asians) is ≥ 1% (minor allele frequency \[MAF\] ≥ 0.01). **Caution:** An allele frequency of ≥ 1% in subpopulations with a low-diversity gene pool (examples: Finnish population, founder mutations!) is not sufficient.

1.2 Variants with a calculated multifactorial probability of \< 0.001 of being pathogenic.

**Caution:** This currently only applies to the high-risk genes *BRCA1/2* (for an exemplary calculation, see [@R11100909-13] ).

1.3   Variants in high-risk genes which occur in at least 10 individuals in appropriate cohorts of persons without disease ( [Table 1](#TB11100909-1){ref-type="table"} ).

**2.   Class2 (probably no loss of function/functionally irrelevant) if one of the following criteria are met:**

2.1   Allele frequency of variants in large population groups (e.g. Caucasians, Africans, or Asians) is 0.5 -- 1% (MAF 0.005 -- 0.01) **Caution:** An allele frequency of 0.5 -- 1% in subpopulations with a low-diversity gene pool (examples: Finnish population, founder mutations!) is not sufficient.

2.2   Exonic variants (A) which result in substitution of an amino acid (missense variants) or small in-frame insertions/deletions (insertions/deletions of one or fewer amino acid \[s\]) and whose a priori probability of pathogenicity is ≤ 2% (A-GVGD analysis, <http://priors.hci.utah.edu/PRIORS/> ); intronic variants (B) which are **more than − 20 bp, + 10 bp from the exon border** ; and synonymous variants (C) if these variants (A -- C) will, according to bioinformatic prediction programmes (see Appendix A 1), in all probability not change the splicing mechanism. In non- *BRCA1/2* genes, the above-mentioned variants must be present in large population groups with an allele frequency of 0.001 ≤ MAF \< 0.01.

2.3   Synonymous substitutions or intronic variants which show no mRNA aberrations in the form of exon deletions/duplications or monoallelic expression of the wildtype (wt) transcript in "in-vitro" laboratory tests even if, according to bioinformatic prediction programmes (see Appendix A 1 for programmes and threshold values), in all probability they change the splicing mechanism.

2.4   Variants which occur in the same gene with a clearly pathogenic variant in trans (co-occurrence), if it has been verified that a homozygous or compound heterozygous genotype is associated with a known, clinically unambiguous phenotype.

2.5 Variants with a calculated multifactorial probability of pathogenicity of 0.001 -- 0.049.

**Caution:** This currently only applies to the high-risk genes *BRCA1/2* (for an exemplary calculation, see: [@R11100909-13] ).

2.6 Exon variants which code for the same amino acid exchange as a sequence variant which has already been classified as Class1 but are based on a different nucleotide exchange if no aberrant splicing is predicted.

2.7  Missense variants for which information from functional analyses, etc., is available but not sufficient for multifactorial classification and which have been classified as Class2 by a panel of experts (e.g. ENIGMA).

**3.   Class3 (unclear functional relevance) if one of the following criteria is met: variants which cannot be unambiguously assigned to Class1, Class2, Class4, or Class5, e.g.:**

3.1   Special cases which could be assigned to one of the other classes based on the evaluation criteria but are listed in Appendix A 5 among the characteristics of individual core genes or in Table 5, Appendix of *BRCA1/2* classification criteria, Version 2.5.1, July 2017 (ENIGMA) ( [Table 5](#TB11100909-5){ref-type="table"} ).

3.2   Variants where the data used for their evaluation is contradictory and for which further studies are still required.

3.3   Variants which are **− 20 bp, + 10 bp from the exon border** and which, based on bioinformatic predictive programmes (see Appendix A 1), probably change the splicing mechanism as long as no in-vitro mRNA analysis has been done yet ( [Fig. 2](#FI11100909-2){ref-type="fig"} , Schematic representation of variants in the vicinity of splice sites).

3.4  Exon duplications which have not been analysed further (e.g. break point analysis, cDNA analysis, etc.).

3.5 Variants with a calculated multifactorial probability of pathogenicity of 0.05 -- 0.949.

**Caution:** This currently only applies to the high-risk genes *BRCA1/2* (for an exemplary calculation, see [@R11100909-13] ).

**4.   Class4 (probable loss of function/functionally relevant) if one of the following criteria is met:**

4.1 Variants with a calculated multifactorial probability of pathogenicity of 0.95 -- 0.99.

**Caution:** This currently only applies to the high-risk genes *BRCA1/2* (for an exemplary calculation, see Goldgar et al., 2004 [@R11100909-13] ).

4.2   Variants which code for a premature termination of protein biosynthesis (nonsense or frameshift variants) and do not necessitate the loss of known clinically relevant functional protein domains as long as the location of the stop codon is not downstream from the Nonsense-mediated decay-(NMD-)relevant site, 50 base pairs before the end of the penultimate exon.

4.3  Intronic variants in position ± 1,2 or G \> non-G in the last position of the exon: if there is a positive splicing prediction (see Appendix A 1) and the first 6 bases in the intron are not GTRRGT and an aberrant in-vitro mRNA analysis is **not yet** available (i.e. has not \[yet\] been confirmed by a panel of experts or the pathomechanism of loss of function has been confirmed to be exon skipping or allele-specific transcript expression).

**Exceptions:**

-   A cryptic splice site (AG/GT) in the vicinity is activated and the (predicted) new exon is spliced in-frame **(→ Class3)**

-   The (predicted) skipped exon (or exons) is alternatively spliced in significant quantities **(→ Class3)** .

-   The (predicted) skipped exon (or exons) is spliced in-frame and contains no known functional domain **(→ Class3)**

4.4  Variants which code for the same amino acid exchange as pathogenic missense variants which have already been categorised as Class5 but are caused by another nucleotide exchange and for which there is no positive splicing prediction (see Appendix A 1).

4.5 In-frame deletions (even for just one amino acid) which lead to the loss of a missense variant already categorised as Class5 and which result in the interruption of known, functionally important domains.

4.6 Extensive in-frame deletions which lead to the interruption/loss of known, functionally important domains.

4.7  In-frame insertions verified by in-vitro mRNA analysis which result in the interruption of functionally important domains.

4.8  Variants which lead to mutations of the translation initiation codon (AUG, methionine) and for which there is no evidence (e.g. an alternative start codon in the immediate vicinity) which would support an alternative classification.

4.9 Variants for which information from functional analyses, clinical data, etc., is available but insufficient for a multifactorial classification and which are categorised as Class4 by a panel of experts (e.g. ENIGMA).

**5.  Class5 (loss of function/functionally relevant) if one of the following criteria are met:**

5.1   Variants which code for a premature termination of protein biosynthesis (nonsense or frameshift variants) which prevents the expression of known, clinically relevant, functional protein domains.

5.2   Variants with a calculated multifactorial probability of pathogenicity of \> 0.99.

**Caution:** This currently only applies to the high-risk genes *BRCA1/2* (for an exemplary calculation, see Goldgar et al., 2004 [@R11100909-13] ).

5.3 Splice variants for which a frameshift effect was established by in-vitro mRNA analysis, which leads to a premature termination of protein biosynthesis and prevents the expression of known, clinically relevant, functional protein domains and for which a wild-type transcript of the mutated allele has not been confirmed (monoallelic expression).

5.4 Splice variants for which in-vitro mRNA analysis detected an in-frame deletion/insertion which leads to the interruption or loss of a known, clinically relevant domain or functional inactivation through changes of the protein structure and for which a wild-type transcript of the mutated allele has not been verified (monoallelic expression).

5.5 Copy-number deletion variants which result in the interruption or loss of one or more exons with known, clinically relevant functional domains or lead to a reading frameshift, which results, according to the prediction, in the inactivation of known, clinically relevant, functional domains.

5.6  Copy-number duplication variants of any size, confirmed by laboratory analysis, which duplicate one or more exons and lead to a reading frameshift, which results, according to the prediction, in the inactivation of known, clinically relevant, functional domains.

Appendix
========

A 1. Splicing prediction programmes and their threshold values
--------------------------------------------------------------

The splicing prediction programmes MaxEntScan (MES), Splice Site Finder (SSF), and Human Splicing Finder (HSF) are considered relatively reliable and should therefore be used to evaluate possible effects on the splicing process. MaxEntScan results are considered non-normal for a deviation of delta of ≥ 15% [@R11100909-14] , Human Splicing Finder for a delta of ≥ 4.1% [@R11100909-10] and Splice Site Finder for a deviation of delta of ≥ 5% [@R11100909-14] . An mRNA analysis should be done for evaluation in cases with non-normal prediction (at least two of the three programmes mentioned below). The precondition is that the physiological splice site is recognised by the respective prediction software based on the following threshold values.

The threshold values (calculated for *BRCA1/2* [@R11100909-14] ) are:

1.  MES \> 3

2.  SSF \> 60

3.  HSF \> 80

An approximation of these threshold values can also be for the other genes. Once specific threshold values have been defined, then the defined threshold values must be used.

A 2.
----

[Tables 1](#TB11100909-1){ref-type="table"} and [2](#TB11100909-2){ref-type="table"} .

A 3. Evaluation Criteria Flow Chart
-----------------------------------

[Fig. 1](#FI11100909-1){ref-type="fig"} .

A 4. Schematic Representation of Variants in the Vicinity of Splice Sites
-------------------------------------------------------------------------

[Fig. 2](#FI11100909-2){ref-type="fig"} .

The use of predictive programmes to assess possible splicing effects is obligatory for all new mutations including stop mutations as "rescue" effects can occur through alternative transcripts.

A 5. Characteristics of Individual Genes
----------------------------------------

**The above-mentioned general evaluation criteria should apply to all genes. However, some exceptions, variations and special features are present in specific variants and regions of individual genes, which, for the sake of clarity, are listed below.**

A 5.1 *BRCA1/2*
---------------

The following should be categorised as Class3: truncating *BRCA1* mutations after the amino acid position 1854 and truncating *BRCA2* variants after amino acid position 3308 (they are not categorised as Class1, as structural mutations cannot be excluded). Exception: truncating variants after the polymorphic stop codon p.(Lys3326\*) are classified as dispensable/neutral (Class1) [@R11100909-17] and ENIGMA: p.(Lys3326\*) is a frequently detected polymorphism which is not associated with a higher risk, OR 1.3 -- 1.5 depending on breast or ovarian cancer. This means that variants which lead to a stop downstream from p.(Lys3326\*) will also not be associated with an increased risk of developing disease.

The following should be categorised as Class5 in *BRCA1/2* : all truncating *BRCA1* variants up to the last mutation unequivocally identified as pathogenic at amino acid position 1853 [@R11100909-18] and all truncating *BRCA2* variants up to amino acid position 3308, c.9924C\>G [@R11100909-19] . See ENIGMA *BRCA1,2* functional domains, [Tables 3](#TB11100909-3){ref-type="table"} and [4](#TB11100909-4){ref-type="table"} . **Caution:** Be aware of the potential impact of NMD; the last 50 bp in the penultimate exon and variants in the last exon usually are usually not subject to NMD. The predictive value of RNA analysis of blood may be limited as it does not involve the target tissue.

###### 

**Table 3**  Excerpt from <https://enigmaconsortium.org/wp-content/uploads/2018/10/ENIGMA_Rules_2017-06-29-v2.5.1.pdf> .

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Table 3: Catalogue of BRCA1 conserved domains/motifs and currently known, clinically important amino acid residues, and relevance for classification of *BRCA1* in-frame and terminal exon sequence variants.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------- -------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  RING                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              1                                                 101                                                L22S (c.65T\>C \[p.Leu22Ser\])\                                                                                                                                                                               Class5 if at least one clinically relevant residue is removed. Otherwise Class3.   <http://www.ncbi.nlm.nih.gov/protein/15988069> ; <http://hci-exlovd.hci.utah.edu> ; multifactorial analysis for H41R (c.122A\>G \[p.His41Arg\]) (Whiley et al., 2014).
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         T37K (c.110C\>A \[p.Thr37Lys\])\                                                                                                                                                                                                                                                                 
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         C39R (c.115T\>C \[p.Cys39Arg\])\                                                                                                                                                                                                                                                                 
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         H41R (c.122A\>G \[p.His41Arg\])\                                                                                                                                                                                                                                                                 
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         C44S (c.130T\>A \[p.Cys44Ser\])\                                                                                                                                                                                                                                                                 
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         C44Y (c.131G\>A \[p.Cys44Tyr\])\                                                                                                                                                                                                                                                                 
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         C61G (c.181T\>G \[p.Cys61Gly\])                                                                                                                                                                                                                                                                  

  NES                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               81                                                99                                                 None reported                                                                                                                                                                                                 Class3                                                                             Domain location description (Rodriguez and Henderson, 2000).

  NLS1                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              503                                               508                                                None reported                                                                                                                                                                                                 Class3                                                                             Domain location description (Chen et al., 1996, Thakur et al., 1997).

  NLS2                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              607                                               614                                                None reported                                                                                                                                                                                                 Class3                                                                             Domain location description (Chen et al., 1996, Thakur et al., 1997).

  NLS3                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              651                                               656                                                None reported                                                                                                                                                                                                 Class3                                                                             Domain location description (Chen et al., 1996).

  COILED-COIL                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       1391                                              1424                                               None reported                                                                                                                                                                                                 Class3                                                                             Domain location description (Hu et al., 2000).

  BRCT DOMAINS                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      1650                                              1863                                               T1685A (c.5053A\>G \[p.Thr1685Ala\])\                                                                                                                                                                         Class5 if at least one clinically relevant residue is removed. Otherwise Class3.   Domain boundaries derived from X-ray crystallography data are aa1646-1863 (1T15, <http://www.ncbi.nlm.nih.gov/Structure/mmdb/mmdbsrv.cgi?uid=27907> ), and ENIGMA functional assay data (Monteiro, unpublished).\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         T1685I (c.5054C\>T \[p.Thr1685Ile\])\                                                                                                                                                                                                                                                            Digestion data indicate aa1860-1863 are dispensable based on susceptibility to digestion (Lee et al., 2010), while pathogenic variant data indicate that 1855-1862 are dispensable (Hayes et al., 2000). Position 1854 is implicated as clinically important by the observation that Y1853X (c.5559C\>G \[p.Tyr1853Ter\]) is a recognised high-risk pathogenic variant.\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         V1688del (c.5062_5064del \[p.Val1688del\])\                                                                                                                                                                                                                                                      These combined data indicate that position 1854 or 1855 is the C-terminal border of the BRCT/BRCA1 relevant for the clinical interpretation of sequence variants in exon 24 of BRCA1. That is, a variant predicted to disrupt expression of protein sequence only downstream\* of position 1855 would not be considered clinically important.
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         R1699W (c.5095C\>T \[p.Arg1699Trp\])\                                                                                                                                                                                                                                                            
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         G1706E (c.5117G\>A \[p.Gly1706Glu\])\                                                                                                                                                                                                                                                            
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         A1708E (c.5123C\>A \[p.Ala1708Glu\])\                                                                                                                                                                                                                                                            
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         S1715R (c.5143A\>C \[p.Ser1715Arg\])\                                                                                                                                                                                                                                                            
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         G1738R (c.5212G\>A \[p.Gly1738Arg\])\                                                                                                                                                                                                                                                            
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         L1764P (c.5291T\>C \[p.Leu1764Pro\])\                                                                                                                                                                                                                                                            
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         I1766S (c.5297T\>G \[p.Ile1766Ser\])\                                                                                                                                                                                                                                                            
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         M1775K (c.5324T\>A \[p.Met1775Lys\])\                                                                                                                                                                                                                                                            
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         M1775R (c.5324T\>G \[p.Met1775Arg\])\                                                                                                                                                                                                                                                            
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         C1787S (c.5359T\>A \[p.Cys1787Ser\])\                                                                                                                                                                                                                                                            
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         G1788V (c.5363G\>T \[p.Gly1788Val\])\                                                                                                                                                                                                                                                            
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         V1838E (c.5513T\>A \[p.Val1838Glu\])                                                                                                                                                                                                                                                             

  ^a^ Missense substitutions in specific functional domains that are designated as Class5 pathogenic based on multifactorial likelihood of the posterior probability of pathogenicity \> 0.99 (listed in <http://hci-exlovd.hci.utah.edu> or individual references), and which have no/little effect on the mRNA transcript profile, *unless* the variant results in an aberrant transcript that encodes a discrete in-frame deletion considered informative for the definition of clinically important domains.\                                                                                                                                                                                                                                                                                                                                                                                                         
  \* Typo was corrected in version 2.5.1.\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                
  Note: The following pathogenic exonic variants known to alter mRNA splicing have been excluded from Table 3 above, as justified below:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  

  **Variant**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       **mRNA Change**                                   **Predicted protein change**                       **Reason for exclusion**                                                                                                                                                                                                                                                                         

  *BRCA1* R1495M (c.4484G\>T \[p.Arg1495Met\])                                                                                                                                                                                                                                                                                                                                                                                                                                                                      r.\[4358_4484del, 4358_4675del\]                  p.(Ala1453Glyfs Ter10) -- predominant transcript   Predominant alternate transcript is out of frame. Loss of function is assumed due to loss of full-length transcript from variant allele (Houdayer et al., 2012, Colombo et al., 2013, Santos et al., 2014).                                                                                      

  *BRCA1* E1559K (c.4675G\>A \[p.Glu1559Lys\])                                                                                                                                                                                                                                                                                                                                                                                                                                                                      r.\[4665_4675del\]                                p.(Gln1366Alafs Ter13)                             Alternate transcript is out-of-frame. Level of full-length transcript not assessed (Wappenschmidt et al., 2012).                                                                                                                                                                                 

  *BRCA1* A1623G (c.4868C\>G \[p.Ala1623Gly\])                                                                                                                                                                                                                                                                                                                                                                                                                                                                      r.\[4868_4986del\]                                p.(Ala1623Aspfs Ter16)                             Alternate transcript is out of frame. Variant allele produces some full-length transcripts (Walker et al., 2010).                                                                                                                                                                                

  *BRCA1* D1692N (c.5074G\>A \[p.Asp1692Asn\])                                                                                                                                                                                                                                                                                                                                                                                                                                                                      r.\[4987_5074del, 5074_5075ins5074+1_5074+153\]   p.(Val1665Serfs Ter8) -- predominant transcript    Predominant alternate transcript, based on minigene assay (Ahlborn et al., 2015), is out of frame.                                                                                                                                                                                               
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

###### 

**Table 4**  Excerpt from <https://enigmaconsortium.org/wp-content/uploads/2018/10/ENIGMA_Rules_2017-06-29-v2.5.1.pdf> .

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Table 4: Catalogue of BRCA2 conserved domains/motifs and currently known clinically important amino acid residues, and relevance for classification of *BRCA2* in-frame and terminal exon sequence variants.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ -------------------- ------------------------------ ----------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------- -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  PALB2 Binding                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      10                   40                             None reported                                                                                               Class3                                                                                    Domain location description (Oliver et al., 2009, Xia et al., 2006)

  BRC-1                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              1002                 1036                           None reported                                                                                               Class3                                                                                    <http://www.ncbi.nlm.nih.gov/protein/NP_000050.2>

  BRC-2                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              1212                 1246                           None reported                                                                                               Class3                                                                                    <http://www.ncbi.nlm.nih.gov/protein/NP_000050.2>

  BRC-3                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              1422                 1453                           None reported                                                                                               Class3                                                                                    <http://www.ncbi.nlm.nih.gov/protein/NP_000050.2>

  BRC-4                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              1518                 1549                           None reported                                                                                               Class3                                                                                    <http://www.ncbi.nlm.nih.gov/protein/NP_000050.2>

  BRC-5                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              1665                 1696                           None reported                                                                                               Class3                                                                                    <http://www.ncbi.nlm.nih.gov/protein/NP_000050.2>

  BRC-6                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              1837                 1871                           None reported                                                                                               Class3                                                                                    <http://www.ncbi.nlm.nih.gov/protein/NP_000050.2>

  BRC-7                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              1971                 2005                           None reported                                                                                               Class3                                                                                    <http://www.ncbi.nlm.nih.gov/protein/NP_000050.2>

  BRC-8                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              2051                 2085                           None reported                                                                                               Class3                                                                                    <http://www.ncbi.nlm.nih.gov/protein/NP_000050.2>

  DBD (DNA/DSS1 binding domain -- helical, OB1, OB2, OB3)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            2481                 3186                           W2626C (c.7878G\>C \[p.Trp2626Cys\])\                                                                       Class5 if at least one clinically relevant residue (or all of AA2778-2829) is removed.\   <http://www.ncbi.nlm.nih.gov/protein/NP_000050.2> ; <http://hci-exlovd.hci.utah.edu> .\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         I2627F (c.7879A\>T \[p.Ile2627Phe\])\                                                                       Otherwise Class3.                                                                         Pathogenic variant c.8486G\>A (also recorded as Gln2829Arg) results in a transcript encoding an in-frame exon 19 deletion only (Houdayer et al., 2012), indicating that genetic variation encompassing loss of this entire exon (AA2778-2829) should be considered clinically important. The clinical impact of alteration/deletion of individual amino acids in exon 19 is not yet established.
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         E2663V (c.7988A\>T \[p.Glu2663Val\])\                                                                                                                                                                 
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         T2722R (c.8165C\>G \[p.Thr2722Arg\])\                                                                                                                                                                 
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         D2723G (c.8168A\>G \[p.Asp2723Gly\])\                                                                                                                                                                 
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         D2723H (c.8167G\>C \[p.Asp2723His\])\                                                                                                                                                                 
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         G2748D (c.8243G\>A \[p.Gly2748Asp\])\                                                                                                                                                                 
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         I2778_Q2829del (c.8332_8487del \[p.Ile2778_Gln2829del\])\                                                                                                                                             
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         R3052W (c.9154C\>T \[p.Arg3052Trp\])                                                                                                                                                                  

  NLS1                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               3263                 3269                           None reported                                                                                               Class3                                                                                    Domain local description (Guidugli et al., 2014)

  BRC-9 or TR2                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       3265                 3330                           None reported                                                                                               Class3                                                                                    Note: although amino acids 3270-3305 within this fragment are reported to bind RAD51-DNA filaments (Davies and Pellegrini, 2007), there is no sequence conservation with the BRC repeats located between aa1002 and aa2014. Domain boundaries are derived from x-ray crystallography data are aa3265-3330 (Esashi et al., 2005, Esashi et al., 2007).\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               Case-control and frequency data indicate that BRCA2 c.9976A\>T (p.Lys3326Ter) does not confer a high risk of cancer (OR 1.3--1.5, dependent on breast or ovarian cancer subtype (Meeks et al., 2016), demonstrating that residues at and downstream of 3327 are likely dispensable.\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               Position 3308 is implicated as clinically important by the observation that a nonsense variant c.9924C\>G (p.Tyr3308Ter) is recognized as a high-risk pathogenic variant with known functional relevance (\[Vallee et al., 2016\]; Bayes score 1122 : 1 from a single large kConFab family, Spurdle unpublished data). There is currently no publicly available clinical information to support pathogenicity of nonsense or frameshift variants located between positions 3309 and 3325.\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               These data combined suggest that the C-terminal border of the BRC-9 relevant to the clinical interpretation of sequence variants in exon 27 of BRCA2 lies between 3309 and 3325. That is, a variant predicted to disrupt expression only of protein sequence downstream of position 3325 would be considered unlikely to be clinically important. Further functional and clinical studies are underway to refine risk, if any, for predicted nonsense or frameshift variants downstream of position 3326.

  NLS2                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               3381                 3385                           No                                                                                                          Class3                                                                                    Domain location description (Guidugli et al., 2014).\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               This domain is considered unlikely clinically relevant since it lies downstream of position 3326.

  ^a^ Missense substitutions in denoted functional domains that are designated as Class5 pathogenic based on multifactorial likelihood posterior probability of pathogenicity \> 0.99, and for which there is no/little effect on mRNA transcript profile -- ***unless*** the variant results in an aberrant transcript that encodes a discrete in-frame deletion considered informative to definition of clinically important domains. (Splicing aberrations are reported for *BRCA2* c.7988A\>T \[p.Glu2663Val\] and c.8168A\>G \[p.Asp2723Gly\] (Walker et al., 2010), but these did not lead to complete loss of function of the full length transcript), and missense alterations showed abrogation of functional activity using multiple assays (Walker et al., 2010). An additional conserved region not commonly recognized as a BRCA2 domain/motif is located AA 1110-1183, but no pathogenic missense substitutions have been recorded for this region.\                                                                                                                                                                                                                                                             
  Note -- The following pathogenic exonic variants known to alter mRNA splicing have been excluded from Table 4 above, as justified below:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     

  **Variant**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        **mRNA Change**      **Predicted protein change**   **Reason for exclusion**                                                                                                                                                                              

  *BRCA2* R2659K (c.7976G\>A \[p.Arg2659Lys\])                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       r.\[7806_7976del\]   p.(Ala2603\_ Arg2659del)       Alternate transcript is in-frame but level of full length transcript not assessed (Farrugia et al., 2008)                                                                                             

  *BRCA2* R2659T (c.7976G\>C \[p.Arg2659Thr\])                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       r.\[7806_7976del\]   p.(Ala2603\_ Arg2659del)       Alternate transcript is in-frame but level of full length transcript not assessed (Farrugia et al., 2008)                                                                                             

  *BRCA2* P3039P (c.9117G\>A \[p.Pro3039Pro\])                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       r.\[8954_9117del\]   p.(Val2985 Glyfs\*4)           Allele-specific assay shows out-of-frame transcript (Houdayer et al., 2012)                                                                                                                           
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Other special features are listed in the Appendix of the evaluation guidelines of the ENIGMA Consortium, which can be accessed via the following link: <https://enigmaconsortium.org/wp-content/uploads/2018/10/ENIGMA_Rules_2017-06-29-v2.5.1.pdf> , Tables 3, 4 and 6 ( [Tables 3](#TB11100909-3){ref-type="table"} to [5](#TB11100909-5){ref-type="table"} ).

A 5.2 *ATM*
-----------

The evaluation criteria for *ATM* are based on a combination of the following criteria:

-   The 5-class IARC system for the assessment of the pathogenicity of *BRCA1* and *BRCA2* variants.

-   The 3-class system to evaluate the pathogenicity of *ATM* variants [@R11100909-20] which includes in silico analyses such as Align-GVGD.

-   The ACMG guidelines on the classification of variants [@R11100909-3] ,  [@R11100909-21] .

-   Additional literature: [@R11100909-22] ,  [@R11100909-23] ,  [@R11100909-24] ,  [@R11100909-25] ,  [@R11100909-26] ,  [@R11100909-27] ,  [@R11100909-28] .

Class1:

-   If the allele frequency is ≥ 1% (MAF ≥ 0.01) in large population groups (e.g. Caucasians, Africans, or Asians) or there is evidence of homozygous variant carriers in control populations. If this is the case, then the variant is always categorised as Class1. An allele frequency of ≥ 1% in subpopulations with a low-diversity gene pool (examples: Finnish population, founder mutations!) is not sufficient.

Class2:

-   If the allele frequency is ≥ 0.5--\< 1% (MAF ≥ 0.005 -- 0.099) in large population groups (e.g. Caucasians, Africans, or Asians), the variant is always categorised as Class2.

-   Missense variants which, according to in silico analysis (Align-GVGD, SIFT), are very probably neutral and/or outside the functionally critical domain (FATKIN).

Class3:

-   All variants which cannot be categorised as Class1, 2, 4 or 5.

Class4:

-   Variants with an in-frame deletion which are within the functionally critical domain (FATKIN).

-   Missense variants which are within the functionally critical domain (FATKIN) and are, according to in silico analysis (Align-GVGD, SIFT), very probably harmful and described as functionally inactive.

Class5:

-   Truncating *ATM* variants up to the FATKIN domain.

-   Missense variants, in-frame deletion or splice mutations which reduce ATM protein expression to \< 20% for the mutated allele [@R11100909-28] ,  [@R11100909-29] .

-   Variants associated with classic AT.

Splice variants: see *BRCA1* and *BRCA2* .

Functional domains: FATKIN with FAT; PI3K-related kinase; FATC

[Table 6](#TB11100909-6){ref-type="table"} .

###### 

**Table 6**   *ATM* , functional domains and relevance for the interpretation of the clinical importance of sequence variants -- catalogue of clinically relevant functional domains and amino acids.

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Region              AA start   AA end   AA alterations with demonstrated clinical importance (AT) characterising known functional domains   References and summary interpretation
  ------------------- ---------- -------- --------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Substrate binding   91         97       None reported                                                                                       Domain location description [@R11100909-30]\
                                                                                                                                              Also contains p53- and BRCA1-binding domain

  NLS                 385        388      None reported                                                                                       Domain location description [@R11100909-28] ,  [@R11100909-31]

  Leucine zipper      1218       1238     None reported                                                                                       Domain location description [@R11100909-25] ,  [@R11100909-28]

  Proline rich        1373       1382     None reported                                                                                       Domain location description [@R11100909-25] ,  [@R11100909-28]

  FATKIN              1893       3056     Yes, e.g.\                                                                                          AA alterations and in-frame deletions [@R11100909-26] ,  [@R11100909-28] ,  [@R11100909-29] ,  [@R11100909-32] ,  [@R11100909-33] ,  [@R11100909-34] ,  [@R11100909-35]\
                                          p.(Val2424Gly)\                                                                                     Domain location description [@R11100909-25] ,  [@R11100909-27] ,  [@R11100909-28] ,  [@R11100909-36] ,  [@R11100909-37]\
                                          p.(2546_2548del), in frame\                                                                         **Domains:**\
                                          p.(Asp2625Glu)\                                                                                     FAT: 1893-2612\
                                          p.(Ala2626Pro)\                                                                                     KIN: 2612-3056 with ATP-binding: 2716-2730, substrate (nibrin and p53) binding: 2682-3012, FATC with TIP60 binding: 3034-3056\
                                          p.(Val2716Ala)\                                                                                     Domain location description
                                          p.(Ser2855_Val2856delinsArgIle)                                                                     
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Additional literature: [@R11100909-22] ,  [@R11100909-23] ,  [@R11100909-24] ,  [@R11100909-25] ,  [@R11100909-26] ,  [@R11100909-28] ,  [@R11100909-33] ,  [@R11100909-35] ,  [@R11100909-38] .

A 5.3 *PALB2*
-------------

-   The p.(Leu939Trp) mutation should be categorised as Class2 [@R11100909-39] .

Additional literature: [@R11100909-35] ,  [@R11100909-38] ,  [@R11100909-40] ,  [@R11100909-41] ,  [@R11100909-42] ,  [@R11100909-43] ,  [@R11100909-44] ,  [@R11100909-45] ,  [@R11100909-46] .

[Table 7](#TB11100909-7){ref-type="table"} .

###### 

**Table 7**   *PALB2* , functional domains and relevance for the interpretation of the clinical importance of sequence variants -- catalogue of clinically relevant functional domains and amino acids.

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Region                               AA start   AA end   AA alterations with potential clinical importance   References and summary interpretation
  ------------------------------------ ---------- -------- --------------------------------------------------- -----------------------------------------------------------------------------------------------------------------------------------------------
  BRCA1 interaction domain             9          43       Yes, e.g.\                                          Also covers oligomerisation domain/covers coiled-coiled motif\
                                                           p.(Leu35Pro)                                        Domain location description [@R11100909-47] ,  [@R11100909-48] ,  [@R11100909-49] ;\
                                                                                                               Amino acid alteration in VUS and functional analysis [@R11100909-50] .

  DNA-binding site                     1          200      None reported                                       Domain location description [@R11100909-51]

  RAD51 binding site                   101        184      None reported                                       Domain location description [@R11100909-51] ,  [@R11100909-52]

  DNA-binding site                     372        561      None reported                                       Covers also chromatin association motif (ChAM, 395-446)\
                                                                                                               Domain location description [@R11100909-51] ,  [@R11100909-53]

  MRG15 (MORF4L1) interaction domain   611        764      None reported                                       Domain location description [@R11100909-48]

  WD40 repeat                          853        1186     Yes, e.g.\                                          BRCA2 (1019-1098), RAD51C, XRCC3 and/or RAD51 complex formation\
                                                           p.(Thr1030Ile)\                                     Domain location description [@R11100909-51] ,  [@R11100909-52] ,  [@R11100909-54] ,  [@R11100909-55] ,  [@R11100909-56] ,  [@R11100909-57] .\
                                                           p.(Leu1143Pro)                                      Amino acid alterations [@R11100909-48] ,  [@R11100909-54] ,  [@R11100909-58]
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

A 5.4 *CHEK2*
-------------

In exons 11 -- 15, highly homologous, functionally inactive sequences (pseudogenes) on various other chromosomes (2, 7, 10, 13, 15, 16, X, and Y) [@R11100909-59] ,  [@R11100909-60] which can superimpose the relevant sequences \> long-range PCR of exons 11 -- 15 and bioinformatic filtering of pseudogene reads, where possible.

Functional domains: SQ/TQ-rich domain\*, forkhead-associated (FHA)\*\* domain, kinase domain\*\*\*, nuclear localisation signal (NLS) [@R11100909-61] ,  [@R11100909-62] ,  [@R11100909-63] .

-   To date, only truncating variants in the SQ/TQ-rich domain have been classified as pathogenic ( [Table 8](#TB11100909-8){ref-type="table"} ).

###### 

**Table 8**   *CHEK2* , functional domains and relevance for the interpretation of the clinical importance of sequence variants -- catalogue of clinically relevant functional domains and amino acids.

  Region       AA start     AA end        AA alterations with Potential Clinical Importance                                                                                                                     References and summary interpretation
  ------------ ------------ ------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------
  SQ/TQ-rich   19           69            e.g. c.85C\>T,p.Gln29\*                                                                                                                                               [@R11100909-62] ,  [@R11100909-65]
  FHA          92 \[115\]   205 \[175\]   p.Arg117Gly, p.Arg145Trp, p.Gly167Arg                                                                                                                                 [@R11100909-61] ,  [@R11100909-62] ,  [@R11100909-63]
  Kinase       212          501           c.1040A\>C, p.Asp347Ala \#; c.1100del; c.1164dup; p.Thr476Met, c.1169A\>C, p.Tyr390Ser; c.1183G\>T, p.Val395Phe\#; c.1283C\>T, p.Ser428Phe; c.1427C\>T, p.Thr476Met   [@R11100909-61] ,  [@R11100909-62] , \#ClinVar
  NLS          515          538           e.g. c.1547delC, p.Ser516Leufs\#; c.1555C\>T, p.Arg519Ter\#;                                                                                                          [@R11100909-63] , \#ClinVar

-   Numerous known missense variants in the FHA domain. **Caution:** Consult FLOSSIES database during evaluation! (e.g. c.470C\>T; p.Ile157Thr: Class2 \[see ^§^ footnote [Table 8](#TB11100909-8){ref-type="table"} ) or with unclear clinical relevance (e.g. c.434G\>A, p.Arg145Gln; c.422A\>C, p.Lys141Thr).

-   Missense variants in the kinase domain with unclear clinical relevance: e.g. c.1216C\>T, p.Arg406Cys.

-   Similarly, in the NLS domain, only truncating variants have been classified as pathogenic to date ( [Table 8](#TB11100909-8){ref-type="table"} ).

The investigation by Ow et al. [@R11100909-63] gives an overview of the identified mutations in the *CHEK2* gene region. The publication by Roeb et al. (2012) includes a schematic overview of the functional domains as well as the results of functional analyses of the missense mutations located in these different *CHEK2* domains [@R11100909-62] .

A 5.5 *TP53*
------------

-   IARC *TP53* database; the functional analyses by Kato et al. (2003) and Monti et al. (2007, 2011) are reliable [@R11100909-72] ,  [@R11100909-73] ,  [@R11100909-74] ,  [@R11100909-75] ,  [@R11100909-76] ,  [@R11100909-77] .

-   Functional domains: oligomerisation domain, core domain (DNA-binding).

-   Possible dominant negative effect of missense variants and stop variants which affect the oligomerisation domain.

-   Mosaic mutations and clonal haematopoiesis are possible, therefore watch out for the variant allele fraction when carrying out NGS analysis; if necessary, carry out further analysis to confirm germline mutations.

[Table 9](#TB11100909-9){ref-type="table"} .

###### 

**Table 9**   *p53* , functional domains and relevance for the interpretation of the clinical importance of sequence variants -- catalogue of clinically relevant functional domains and amino acids.

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Region                                     AA start   AA end   AA alterations with demonstrated clinical importance (including conflicting interpretations of pathogenicity but criteria provided)   References and summary interpretation
  ------------------------------------------ ---------- -------- ------------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------
  Transcription activation                   1          55       p.(Val10Ile)\                                                                                                                         Amino acid alterations (ClinVar)\
                                                                 p.(Val31Ile)\                                                                                                                         Domain location description [@R11100909-78]\
                                                                 p.(Pro47Ser)                                                                                                                          Also binding site for numerous proteins including HDM2 (amino acids 15-29; IARC)

  Proline-rich domain                        61         94       p.(Pro82Leu)\                                                                                                                         Amino acid alterations (ClinVar)\
                                                                 p.(Ala83Val)                                                                                                                          Domain location description [@R11100909-78]

  DNA-binding region                         102        292      p.(Gly105Asp)\                                                                                                                        Amino acid alterations (ClinVar)\
                                                                 p.(Lys120Glu)\                                                                                                                        Domain location description (IARC)\
                                                                 p.(Thr125Met)\                                                                                                                        Also binding site for numerous proteins including 53BP1 (IARC) and RAD51 amino acids 94-160 and 264-315 [@R11100909-79]
                                                                 p.(Ser127Phe)\                                                                                                                        
                                                                 p.(Asn131Tyr)\                                                                                                                        
                                                                 p.(Cys141Tyr)\                                                                                                                        
                                                                 p.(Pro151Ser)\                                                                                                                        
                                                                 p.(Pro151Thr)\                                                                                                                        
                                                                 p.(Pro152Leu)\                                                                                                                        
                                                                 p.(Arg156His)\                                                                                                                        
                                                                 p.(Arg158Cys)\                                                                                                                        
                                                                 p.(Arg158His)\                                                                                                                        
                                                                 p.(Tyr163Asp)\                                                                                                                        
                                                                 p.(Tyr163Cys)\                                                                                                                        
                                                                 p.(Arg175Leu)\                                                                                                                        
                                                                 p.(Arg175His)\                                                                                                                        
                                                                 p.(Cys176Tyr)\                                                                                                                        
                                                                 p.(His179Tyr)\                                                                                                                        
                                                                 p.(Arg181Cys)\                                                                                                                        
                                                                 p.(Arg181His)\                                                                                                                        
                                                                 p.(Ala189Val)\                                                                                                                        
                                                                 p.(His193Arg)\                                                                                                                        
                                                                 p.(His193Leu)\                                                                                                                        
                                                                 p.(Leu194Phe)\                                                                                                                        
                                                                 p.(Ile195Thr)\                                                                                                                        
                                                                 p.(Arg213Gln)\                                                                                                                        
                                                                 p.(Val.216Met)\                                                                                                                       
                                                                 p.(Tyr220Cys)\                                                                                                                        
                                                                 p.(Tyr220Ser)\                                                                                                                        
                                                                 p.(Ile232Thr)\                                                                                                                        
                                                                 p.(Tyr234Cys)\                                                                                                                        
                                                                 p.(Asn235Ser)\                                                                                                                        
                                                                 p.(Tyr236Asp)\                                                                                                                        
                                                                 p.(Met237Val)\                                                                                                                        
                                                                 p.(Met237Ile)\                                                                                                                        
                                                                 p.(Cys238Tyr)\                                                                                                                        
                                                                 p.(Ser241Phe)\                                                                                                                        
                                                                 p.(Cys242Tyr)\                                                                                                                        
                                                                 p.(Gly245Asp)\                                                                                                                        
                                                                 p.(Gly245Ser)\                                                                                                                        
                                                                 p.(Gly245Cys)\                                                                                                                        
                                                                 p.(Met246Val)\                                                                                                                        
                                                                 p.(Met246Leu)\                                                                                                                        
                                                                 p.(Met246Arg)\                                                                                                                        
                                                                 p.(Arg248Gln)\                                                                                                                        
                                                                 p.(Arg248Trp)\                                                                                                                        
                                                                 p.(Ile251Leu)\                                                                                                                        
                                                                 p.(Ile251Ser)\                                                                                                                        
                                                                 p.(Thr256Ala)\                                                                                                                        
                                                                 p.(Leu257Arg)\                                                                                                                        
                                                                 p.(Glu258Lys)\                                                                                                                        
                                                                 p.(Arg267Trp)\                                                                                                                        
                                                                 p.(Arg267Gln)\                                                                                                                        
                                                                 p.(Val272Leu)\                                                                                                                        
                                                                 p.(Arg273Hisv\                                                                                                                        
                                                                 p.(Arg273Cys)\                                                                                                                        
                                                                 p.(Cys275Tyr)\                                                                                                                        
                                                                 p.(Cys277Tyr)\                                                                                                                        
                                                                 p.(Arg280Thr)\                                                                                                                        
                                                                 p.(Asp281Val)\                                                                                                                        
                                                                 p.(Asp281Gly)\                                                                                                                        
                                                                 p.(Arg282Gly)\                                                                                                                        
                                                                 p.(Arg282Leu)\                                                                                                                        
                                                                 p.(Arg282Trp)\                                                                                                                        
                                                                 p.(Arg283His)\                                                                                                                        
                                                                 p.(Arg283Lys)\                                                                                                                        
                                                                 p.(Glu286Lys)                                                                                                                         

  Oligomerisation region                     325        356      p.(Gly325Val)\                                                                                                                        Amino acid alterations (ClinVar)\
                                                                 p.(Arg337Leu)\                                                                                                                        Domain location description (IARC)\
                                                                 p.(Arg337Cys)\                                                                                                                        Also binding site for numerous proteins\
                                                                 p.(Glu339Lys)\                                                                                                                        Covering main nuclear localisation signal (amino acids 316-322) [@R11100909-80] ,  [@R11100909-81]
                                                                 p.(Arg342Pro)                                                                                                                         

  Basic (repression of DNA-binding region)   369        388      None reported                                                                                                                         Domain location description (IARC)\
                                                                                                                                                                                                       Also binding site for numerous proteins including RAD54 [@R11100909-82]
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

A 5.6 *RAD51D*
--------------

Functional domains: N-terminal domains and ATP-binding domain with the highly conserved Walker A and B motifs [@R11100909-83] , [@R11100909-84] , [@R11100909-85] .

[Table 10](#TB11100909-10){ref-type="table"} .

###### 

**Table 10**   *RAD51D* , functional domains and relevance for the interpretation of the clinical importance of sequence variants -- catalogue of clinically relevant functional domains and amino acids.

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Region                                                AA start   AA end   AA alterations with demonstrated clinical importance (including conflicting interpretations of pathogenicity)   References and summary interpretation
  ----------------------------------------------------- ---------- -------- --------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------
  N-terminal region                                     1          83       None reported                                                                                                   N-terminal domain required for ssDNA-specific binding function [@R11100909-86]

  Linker                                                60         78       None reported                                                                                                   Proper interaction with RAD51C and XRCC2 [@R11100909-85]

  ATPase domain and RAD51B, RAD51C, and XRCC2 binding   99         274      p.(G112A) (disrupts binding of RAD51D to RAD51C [@R11100909-87] )\                                              ATPase, AAA+ type\
                                                                            p.(S207L) (disrupts RAD51D-XRCC2 interaction [@R11100909-85] )\                                                 Walker A and B motifs crucial for HR. These motifs are also implicated in binding to RAD51C and XRCC2.
                                                                            p.(A210V) (predicted to be potentially pathogenic [@R11100909-88] ,  [@R11100909-89] )\                         
                                                                            p.(R266C) [@R11100909-90] , Meindl et al. (unpublished)                                                         
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Additional literature: [@R11100909-91] ,  [@R11100909-92] ,  [@R11100909-93] ,  [@R11100909-94]

A 5.7 *RAD51C*
--------------

References: [@R11100909-91] ,  [@R11100909-95]  --  [@R11100909-101]

Functional domains: DNA repair/recombination protein RecA-like, ATP-binding domain

[Table 11](#TB11100909-11){ref-type="table"} .

###### 

**Table 11**   *RAD51C* , functional domains and relevance for the interpretation of the clinical importance of sequence variants -- catalogue of clinically relevant functional domains and amino acids.

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Region                                                AA start   AA end   AA alterations with demonstrated clinical importance (including conflicting interpretations of pathogenicity)   References and summary interpretation
  ----------------------------------------------------- ---------- -------- --------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  N-terminal region                                     1          66       None reported                                                                                                   Homology-derived putative DNA-binding domain [@R11100909-91]

  ATPase domain and RAD51B, XRCC3, and RAD51D binding   79         376      p.(Gly125Val)\                                                                                                  Amino acid alterations and functional consequences [@R11100909-95] ,  [@R11100909-96] ,  [@R11100909-97] ,  [@R11100909-98] Domain location description [@R11100909-91] ATPase domain includes Walker A nucleotide binding motif (amino acids 125-132) and Walker B nucleotide binding motif (amino acids 238-242) [@R11100909-91] ,  [@R11100909-99]
                                                                            p.(Cys135Tyr)\                                                                                                  
                                                                            p.(Leu138Phe)\                                                                                                  
                                                                            p.(Gly153Asp)\                                                                                                  
                                                                            p.(Asp159Asn)\                                                                                                  
                                                                            p.(Val169Ala)\                                                                                                  
                                                                            p.(Leu219Ser)\                                                                                                  
                                                                            p.(Arg258His)\                                                                                                  
                                                                            p.(Gly264Ser)                                                                                                   

  Nuclear localisation signal                           366        370      None reported                                                                                                   Domain location description [@R11100909-99]
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

A 5.8 *BRIP1*
-------------

[Table 12](#TB11100909-12){ref-type="table"} .

###### 

**Table 12**   *BRIP1* , functional domains and relevance for the interpretation of the clinical importance of sequence variants -- catalogue of clinically relevant functional domains and amino acids.

  Region                                   AA start   AA end   AA alterations with demonstrated clinical importance (including conflicting interpretations of pathogenicity)   References and summary interpretation
  ---------------------------------------- ---------- -------- --------------------------------------------------------------------------------------------------------------- ----------------------------------------------
  DEAD/DEAH box helicase domain            17         441                                                                                                                      Domain location description [@R11100909-102]
  Helicase superfamily c-terminal domain   697        851                                                                                                                      Domain location description [@R11100909-102]
  The BRCA1 interacting region of BRIP1    976        1006     Phosphorylation of FANCJ at Ser-990 is important for its interaction with BRCA1                                 [@R11100909-103]
  MLH1 interaction                                             Lysines 141 and 142 are required for direct interaction of FANCJ with MLH1                                      [@R11100909-104]
  Nuclear localisation signal              158        175      None reported                                                                                                   Domain location description [@R11100909-102]

Additional literature: [@R11100909-1] ,  [@R11100909-102] ,  [@R11100909-105] ,  [@R11100909-106] ,  [@R11100909-107] ,  [@R11100909-108] ,  [@R11100909-109] ,  [@R11100909-110]

A 5.9 CDH1
----------

References:

Focuses predominantly on molecular genetics: [@R11100909-111]

Review of functional analyses: [@R11100909-112]

Review of the HDGC Consortium: [@R11100909-113]

Review of lobular breast cancer: [@R11100909-114]

Distribution of pathogenic variants at the *CDH1* locus [@R11100909-111]

Known pathogenic CDH1 variants are distributed across the entire locus; it is therefore not possible to define a clinically relevant functional protein domain. The last known truncating pathogenic variant in the last exon is c.2506G\>T (p.Glu836\*) [@R11100909-115] . All truncating variants upstream must therefore be categorised at least as Class4.

The proposal put forwards by the ClinGen Consortium to categorise variants with a MAF \> 0.2% as ACMG Class1, contrary to IARC guidelines, is currently being debated.

CDH1 Rule Specifications for the ACMG/AMP Variant Curation Guidelines ClinGen ( <https://www.clinicalgenome.org/site/assets/files/8816/clingen_cdh1_acmg_specifications_v1.pdf> ).
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International Agency for Research on Cancer.

High-risk genes: at least one sequence variant with an odds ratio for breast and/or ovarian cancer of \> 5 (e.g. BRCA1, BRCA2, RAD51C, PALB2, TP53, ATM), see [@R11100909-1] ,  [@R11100909-2] .

Evidence-based network for the interpretation of germline mutant alleles: <http://enigmaconsortium.org/>

American College of Medical Genetics and Genomics (ACMG [@R11100909-3] ).

Association for Clinical Genomic Science (ACGS, <http://www.acgs.uk.com/> ).

International Agency for Research on Cancer.

Hochrisikogene: mind. eine Sequenzvariante mit Odds Ratio für Brust- und/oder Eierstockkrebs OR \> 5 (z.B. BRCA1, BRCA2, RAD51C, PALB2, TP53, ATM), siehe auch [@R11100909-1] ,  [@R11100909-2] .

Evidence based Network for the Interpretation of Germline Mutant Allels, <http://enigmaconsortium.org/>

American College of Medical Genetics and Genomics (ACMG [@R11100909-3] ).

Association for Clinical Genomic Science (ACGS, <http://www.acgs.uk.com/> ).

Kriterien des Deutschen Konsortiums Familiärer Brust- und Eierstockkrebs zur Klassifizierung von Keimbahn-Sequenzvarianten in Risikogenen für familiären Brust- und Eierstockkrebs

Das Deutsche Konsortium für Familiären Brust- und Eierstockkrebs (GC-HBOC) etablierte vor über 10 Jahren eine Expertengruppe (VUS Task Force), um die von den einzelnen Zentren des GC-HBOC an die zentrale Datenbank in Leipzig gemeldeten Varianten hinsichtlich ihrer Klassifizierung zu überprüfen und ggf. nach aktueller Datenlage neu einzustufen. Die innerhalb der VUS-Task Force konsentierten Variantenbewertungen und resultierenden -klassifizierungen werden in einer zentralen Datenbank hinterlegt und sind als Grundlage zu berücksichtigen, um eine einheitliche Bewertung bereits bekannter wie auch neu identifizierter Varianten innerhalb der verschiedenen Zentren des GC-HBOC zu gewährleisten. Die standardisierte VUS-Bewertung durch die VUS Task Force ist ein zentrales Element des vom GC-HBOC ebenfalls etablierten Recall-Systems. Dieses dient der Weitergabe der Informationen an die in den Zentren betreuten Familien im Falle einer aufgrund neuer Erkenntnisse aktualisierten Neubewertung von bereits klassifizierten Varianten. Die in Anlehnung an international etablierte Bewertungsverfahren (IARC, ACMG, ENIGMA) angepassten Bewertungsalgorithmen der VUS Task Force werden in diesem Artikel anhand der zugrundeliegenden Entscheidungskriterien präsentiert, die gemäß eines priorisierenden Fließschemas zum Klassifizierungsergebnis führen. Weiterhin werden genspezifische Regelungen und Besonderheiten, die für einzelne mit Brust- und/oder Eierstockkrebs assoziierte Risikogene zu berücksichtigen sind, in einzelnen Unterkapiteln dargelegt. Um dem Umfang und der Dynamik des aktuellen Wissens zur Variantenbewertung gerecht zu werden, sind neben umfangreichen Literaturverweisen insbesondere auch die URLs von relevanten Datenbanken angegeben. In Zukunft sollen an neue Erkenntnisse angepasste Kriterien auf der Webseite von GC-HBOC ( <https://www.konsortium-familiaerer-brustkrebs.de/> ) veröffentlicht werden.

familiärer Brust-/Eierstockkrebs

Klassifikation genetischer Varianten

Risikogene

Allgemeine Grundlagen
=====================

Die Kriterien des Deutschen Konsortiums Familiärer Brust- und Eierstockkrebs ( <http://www.konsortium-familiaerer-brustkrebs.de/> ) zur Klassifizierung von Keimbahn-Sequenzvarianten in Risikogenen für Brust-und Eierstockkrebs wurden durch die oben genannten Mitglieder des Expertengremiums zur Variantenbewertung (VUS Task-Force) des Deutschen Konsortiums Familiärer Brust- und Eierstockkrebs erarbeitet. Aufgabe dieser Expertengruppe ist es, innerhalb des Deutschen Konsortiums Familiärer Brust- und Eierstockkrebs verbindliche Kriterien für die Bewertung von Varianten vorzugeben und die Klassifizierung von Varianten zu überprüfen um eine einheitliche Bewertungen von Varianten innerhalb des Konsortiums sicherzustellen. Die vorliegenden Kriterien beruhen auf einem IARC [^1^](#FN11100909de-1){ref-type="fn"} 5-Klassen-System für Hochrisikogene [^2^](#FN11100909de-2){ref-type="fn"} basierend auf den Richtlinien des ENIGMA [^3^](#FN11100909de-3){ref-type="fn"} -Konsortiums (ENIGMA *BRCA1/2* classification criteria Version 2.5.1, June 2017) sowie den ACMG [^4^](#FN11100909de-4){ref-type="fn"} - und ACGS [^5^](#FN11100909de-5){ref-type="fn"} -Richtlinien. Innerhalb dieses 5-Klassen-Systems erfolgt eine Bewertung von Sequenzvarianten der Keimbahn hinsichtlich ihrer Relevanz für einen Funktionsverlust des codierten Proteins (Class1: neutral, Class2: wahrscheinlich neutral, Class3: unklare Datenlage/keine sichere Bewertung, Class4: wahrscheinlicher relevanter Funktionsverlust, Class5: relevanter Funktionsverlust; Signifikanzlevel, siehe [@R11100909-4] ). Für Gene mit hoher Penetranz (wie z. B. *BRCA1, BRCA2* ), für die eine klinische Korrelation (Pathogenität) mit einem Funktionsverlust beschrieben ist, ergibt die funktionelle Klassifizierung eine Pathogenitätsbeurteilung entsprechend dem IARC-5-Klassensystem (Class1: not pathogenic bis Class5: pathogenic), siehe Anhang A 2, [Tab. 1](#TB11100909DE-1){ref-type="table"} . Vorteil dieses strukturierten Vorgehens ist, dass zunächst Kriterien abgefragt werden, die eine schnelle und eindeutige Klassifizierung erlauben und erst im Anschluss eine umfangreiche Daten- und Literaturrecherche erfolgt (siehe Anhang A 2, [Tab. 2](#TB11100909DE-2){ref-type="table"} : Übersicht relevanter Datenbanken und A 3, [Abb. 1](#FI11100909DE-1){ref-type="fig"} : Fließschema zu den Bewertungskriterien). Hinsichtlich der Klassifizierung von Sequenzvarianten der Gene *ATM, BRCA1, BRCA2, BRIP1, CDH1, CHEK2, PALB2, RAD51C, RAD51D* und *TP53* , den sogenannten „Core"-Genen des TruRisk-Panels (Version 1/2018, siehe unter: Homepage des Deutschen Konsortiums, <http://www.konsortium-familiaerer-brustkrebs.de/> ) sind die in Anhang A 5 aufgeführten Besonderheiten zu berücksichtigen. Bei moderat/niedrig-penetranten Genen erfolgt dagegen lediglich eine Bewertung bezüglich ihrer Funktionalität (hier: Funktionsverlust nicht gleichzusetzen mit „Pathogenität"). Auch bei Hochrisikogenen können Varianten nachweislich nur mit einem intermediären Risiko einhergehen [@R11100909-5] ,  [@R11100909-6] .

###### 

**Tab. 1**  IARC 5-tiered classification system with accompanying recommendations for family management ^a^ (Auszug aus <https://enigmaconsortium.org/wp-content/uploads/2018/10/ENIGMA_Rules_2017-06-29-v2.5.1.pdf> ).

  Class                                                         Quantitative measure: probability of pathogenicity   Predictive testing of at-risk relatives   Surveillance of at-risk relatives                                                                                       Research testing of relatives
  ------------------------------------------------------------- ---------------------------------------------------- ----------------------------------------- ----------------------------------------------------------------------------------------------------------------------- -------------------------------
  5: Pathogenic                                                 \> 0.99                                              Yes                                       Full high-risk guidelines for variant carriers                                                                          Not indicated
  4: Likely pathogenic                                          0.95 -- 0.99                                         Yes ^b^                                   Full high-risk guidelines for variant carriers                                                                          Yes
  3: Uncertain                                                  0.05 -- 0.949                                        No ^b^                                    Based on family history & other risk factors                                                                            Yes
  2: Likely not pathogenic or of little clinical significance   0.001 -- 0.049                                       No ^b^                                    Based on family history & other risk factors -- treat as „no *BRCA1/2* pathogenic variant detected" for this disorder   Yes
  1: Not pathogenic or of no clinical significance              \< 0.001                                             No ^b^                                    Based on family history & other risk factors -- treat as „no *BRCA1/2* pathogenic variant detected" for this disorder   Not indicated

###### 

**Tab. 2**  Für die Bewertung relevante Literatur- und Datenbanken.

  Datenbank                                                                                                                                                                         URL
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------
  1000Genomes                                                                                                                                                                       <http://www.1000genomes.org/>
  ARUP *(BRCA1)*                                                                                                                                                                    <http://arup.utah.edu/database/BRCA/Variants/BRCA1>
  ARUP *(BRCA2)*                                                                                                                                                                    <http://arup.utah.edu/database/BRCA/Variants/BRCA2>
  BIC ( **B** reast Cancer **I** nformation **C** ore)                                                                                                                              <http://research.nhgri.nih.gov/bic/>
  BRCA1 CIRCOS (via BIC oder, **Cave:** BIC-Nomenklatur angeben!)                                                                                                                   <https://research.nhgri.nih.gov/projects/bic/circos/search.shtml>
  BRCA Exchange                                                                                                                                                                     <http://brcaexchange.org>
  ClinVar (ClinGen)                                                                                                                                                                 <https://www.ncbi.nlm.nih.gov/clinvar/>
  Database of Functional Classifications of *BRCA1* Variants based on Saturation Genome Editing [@R11100909-15] ,  [@R11100909-16]                                                  <https://sge.gs.washington.edu/BRCA1/>
  dbSNP                                                                                                                                                                             <https://www.ncbi.nlm.nih.gov/snp>
  EVS/ESP                                                                                                                                                                           <http://evs.gs.washington.edu/EVS/>
  Exome Aggregation Consortium ExAC Browser                                                                                                                                         <http://exac.broadinstitute.org/>
  exUV-LOVD (multifaktoriell reklassifizierte *BRCA1/2* -Varianten)                                                                                                                 <http://hci-exlovd.hci.utah.edu/home.php>
  FLOSSIES ( **F** abulous **L** adies **O** ver **S** eventy: Keimbahnvarianten in 27 brustkrebsrelevanten Genen bei ca. 10 000 Frauen \> 70 J., bisher nicht an Krebs erkrankt)   <https://whi.color.com/>
  Genome Aggregation Database GnomAD                                                                                                                                                <http://gnomad.broadinstitute.org/>
  Google Scholar                                                                                                                                                                    <http://scholar.google.de/>
  HGMD Professional (Registrierung erforderlich)                                                                                                                                    <https://portal.biobase-international.com/>
  IARC *TP53* Datenbank                                                                                                                                                             <http://p53.iarc.fr/>
  InSiGHT Consortium (Classification Database)                                                                                                                                      <http://www.insight-database.org/classifications/>
  KAVIAR (Known VARiants, genomic)                                                                                                                                                  <http://db.systemsbiology.net/kaviar/cgi-pub/Kaviar.pl>
  LOVD (Leiden Open Variation Database, allgemein)                                                                                                                                  <http://www.lovd.nl/3.0/home>
  LOVD-Datenbank, *ATM*                                                                                                                                                             <https://databases.lovd.nl/shared/genes/ATM>
  LOVD-Datenbank, *BRCA1*                                                                                                                                                           <https://databases.lovd.nl/shared/genes/BRCA1>
  LOVD-Datenbank, *BRCA2*                                                                                                                                                           <https://databases.lovd.nl/shared/genes/BRCA2>
  LOVD-Datenbank, *BRIP1*                                                                                                                                                           <http://databases.lovd.nl/shared/genes/BRIP1>
  LOVD-Datenbank, *CDH1*                                                                                                                                                            <http://databases.lovd.nl/shared/genes/CDH1>
  LOVD-Datenbank, *CHEK2*                                                                                                                                                           <https://databases.lovd.nl/shared/genes/CHEK2>
  LOVD-Datenbank, *PALB2*                                                                                                                                                           <http://databases.lovd.nl/shared/genes/PALB2>
  LOVD-Datenbank, *RAD51C*                                                                                                                                                          <https://databases.lovd.nl/shared/genes/RAD51C>
  LOVD-Datenbank, *RAD51D*                                                                                                                                                          <https://databases.lovd.nl/shared/genes/RAD51D>
  LOVD-Datenbank, *TP53*                                                                                                                                                            <https://databases.lovd.nl/shared/genes/TP53>
  PubMed                                                                                                                                                                            <http://www.ncbi.nlm.nih.gov/pubmed/>
  *TP53* , PHANTM (Genotyp-Phenotyp-Korrelation)                                                                                                                                    <http://mutantp53.broadinstitute.org/heatMap/login>
  UMD ( **U** niv. **M** utation **D** atabase, LSDB: Locus Specific Databases)                                                                                                     <http://www.umd.be/>
  UMD/BRCAshare- *BRCA1* (Registrierung erforderlich)                                                                                                                               <http://www.umd.be/BRCA1/>
  UMD/BRCAshare- *BRCA2* (Registrierung erforderlich)                                                                                                                               <http://www.umd.be/BRCA2/>
  UMD *TP53*                                                                                                                                                                        <http://p53.fr/tp53-database>
  VarSeak                                                                                                                                                                           <https://varseak.bio/>
  VarSome (automatisierte ACMG-Klassifizierung)                                                                                                                                     <https://varsome.com/>

![ VUS-Bewertungsschema 1.1.](10-1055-a-1110-0909-igfde01){#FI11100909DE-1}

Kriterien zur Interpretation von mRNA-Analysen
==============================================

Die Kriterien des Deutschen Konsortiums familiärer Brust- und Eierstockkrebs zur Bewertung von Sequenzvarianten mit nachfolgender mRNA-Analyse beruhen ebenfalls auf den Richtlinien des ENIGMA-Konsortiums (siehe dazu auch [@R11100909-7] ). Für die empirische, prädiktive Vorhersage von potenziellen Spleißvarianten mittels der 3 häufig verwandten Vorhersageprogramme sind in A 1 die entsprechenden Grenzwerte angegeben. Eine schematische Darstellung der von der VUS-Task-Force betrachteten Bereiche zur Bewertung von Spleißvarianten zeigt A 4 ( [Abb. 2](#FI11100909DE-2){ref-type="fig"} ). Die mRNA-Analysen werden an Frischblut, kultivierten Lymphozyten, kultivierten lymphoblastoiden Zelllinien etc. durchgeführt und parallel mit mindestens 5 Kontrollen gleichen Materialtyps verglichen. Eine Sequenzvariante wird dann als pathogen bezeichnet, wenn diese wie folgt einen Effekt auf die mRNA-Transkription hat: Es werden ausschließlich ein oder mehrere aberrante Transkripte des varianten Allels nachgewiesen, welche zu einem Stopp-Codon oder einer In-Frame-Deletion führen und in der Zerstörung bekannter funktioneller Domänen resultieren. Zur Bestimmung der Transkriptmenge (semiquantitative oder quantitative Methoden) wird die Sequenzierung des Full-Length-Transkripts des varianten Allels oder bei Vorliegen einer intronischen Variante eines in *cis* liegenden Polymorphismus als ausreichend angesehen (Nachweis monoallelischer Expression). Varianten, die dagegen ein Transkriptmuster vergleichbar mit dem Mittelwert der Kontrollen zeigen, werden aufgrund einer fehlenden aberranten mRNA als neutral/nicht pathogen bewertet. Bezüglich des cDNA-Primer-Designs sollten die physiologischen Spleißvarianten/natürlich vorkommenden Isoformen berücksichtigt werden (siehe auch [@R11100909-8] ,  [@R11100909-9] ).

![ Klassifizierung von Varianten, die das Spleißen beeinflussen könnten.](10-1055-a-1110-0909-igfde02){#FI11100909DE-2}

**Cave:** Bestimmte *BRCA1* - und *BRCA2* -Varianten ± 1, 2 bp von der Exongrenze entfernt, welche vorhergesagt oder nachgewiesen per Allel zu mindestens 20 -- 30% natürlich auftretender In-Frame-RNA-Isoformen führen, können vermutlich zu einer noch vorhandenen Restaktivität des Proteins führen (siehe auch [@R11100909-9] , [@R11100909-10] , [@R11100909-11] , [@R11100909-12] ) und werden, wenn nicht anders nachgewiesen, als VUS Class3 bewertet (siehe auch Übersicht, Anhang 5, [Tab. 5](#TB11100909DE-5){ref-type="table"} )

###### 

**Tab. 5**  Auszug aus <https://enigmaconsortium.org/wp-content/uploads/2018/10/ENIGMA_Rules_2017-06-29-v2.5.1.pdf> .

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Table 6: *BRCA1* and *BRCA2* exon boundary variants predicted or known to lead to naturally occurring in-frame RNA isoforms that may rescue gene functionality. *Variants at these positions should be considered Class3 Uncertain unless proven otherwise.\**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- --------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  *BRCA1*                                                                                                                                                                                                                                                          Δ8p                   c.442-1 (IVS7-1)\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              *BRCA1* exon 8 acceptor site is an experimentally validated tandem acceptor site (NAGNAG) subject to alternative splicing (Colombo et al., 2014). c.442-1,-2 variants are predicted to inactivate the 5′ acceptor site, but not the 3′ acceptor site, thus producing Δ8p transcripts.
                                                                                                                                                                                                                                                                                         c.442-2 (IVS7-2)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               

  Δ9,10                                                                                                                                                                                                                                                            c.548-1 (IVS8-1)\     Carriers of variants at these positions are predicted to produce normal (or increased) levels of *BRCA1* Δ(9,10), a major in-frame alternative splicing event (Colombo et al., 2014).\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         
                                                                                                                                                                                                                                                                   c.548-2 (IVS8-2)\     The *BRCA1* variant c.594-2A\>C (shown from ENIGMA research to co-occur in cis with c.641A\>G), has been reported to demonstrate clinical characteristics inconsistent with a high risk of cancer expected for a pathogenic *BRCA1* variant (Rosenthal et al., 2015). The haplotype of c.\[594-2A\>C; 641A\>G\] has been shown from mRNA analysis in human samples to produce high levels of Δ10 transcripts (70% of the overall expression, and **has been designated as Class1 Not Pathogenic** by the ENIGMA Consortium using multifactorial likelihood analysis that includes genetic (segregation, case-control analysis) and pathology data (de la Hoya et al., 2016).   
                                                                                                                                                                                                                                                                   c.593 to non-G\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      
                                                                                                                                                                                                                                                                   c.593+1 (IVS9+1)\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    
                                                                                                                                                                                                                                                                   c.593+2 (IVS9+2)\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    
                                                                                                                                                                                                                                                                   c.594+1 (IVS9-1)\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    
                                                                                                                                                                                                                                                                   c.594-2 (IVS9-2)\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    
                                                                                                                                                                                                                                                                   c.670 to non-G\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      
                                                                                                                                                                                                                                                                   c.670+1 (IVS10+1)\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   
                                                                                                                                                                                                                                                                   c.670+2 (IVS10+2)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    

  Δ11q, Δ11                                                                                                                                                                                                                                                        c.4096 to non-G\      Data collected by the ENIGMA consortium demonstrates that the *BRCA1* c.4096+1G\>A variant, proven to result in the production of naturally occurring in-frame transcripts Δ11q (Bonatti et al., 2006) and also Δ11 (Radice, unpublished data), may not exhibit the clinical characteristics of a standard high-risk pathogenic *BRCA1* variant (Spurdle, unpublished data).                                                                                                                                                                                                                                                                                                   
                                                                                                                                                                                                                                                                   c.4096+1 (IVS11+1)\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  
                                                                                                                                                                                                                                                                   c.4097+2 (IVS11+2)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   

  Δ13p                                                                                                                                                                                                                                                             c.4186-1 (IVS12-1)\   *BRCA1* exon 13 acceptor site is an experimentally validated tandem acceptor site (NAGNAG) subject to alternative splicing (Colombo et al., 2014). c.4186- 1,-2 variants are predicted to inactivate the 5′ acceptor site, but not the 3′ acceptor site, thus producing Δ13p transcripts.                                                                                                                                                                                                                                                                                                                                                                                      
                                                                                                                                                                                                                                                                   c.4186-2 (IVS12-2)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   

  Δ14p                                                                                                                                                                                                                                                             c.4358-1 (IVS13-1)\   *BRCA1* exon 14 acceptor site is an experimentally validated tandem acceptor site (NAGNAG) subject to alternative splicing (Colombo et al., 2014). c.4358-1,-2 variants are predicted to inactivate the 5′ acceptor site, but not the 3′acceptor site, thus producing Δ14p transcripts.                                                                                                                                                                                                                                                                                                                                                                                        
                                                                                                                                                                                                                                                                   c.4358-2 (IVS13-2)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   

  *BRCA2*                                                                                                                                                                                                                                                          Δ12                   c.6842-1 (IVS11-1)\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            Carriers of these variants are predicted to produce exon 12 skipping. BRCA2 Δ12 is a naturally occurring in-frame splicing event (Fackenthal et al., 2016). BRCA2 exon 12 is functionally redundant (Li et al., 2009).
                                                                                                                                                                                                                                                                                         c.6842-2 (IVS11-2)\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            
                                                                                                                                                                                                                                                                                         c.6937 to non-G\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               
                                                                                                                                                                                                                                                                                         c.6937+1 (IVS12+1)\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            
                                                                                                                                                                                                                                                                                         c.6937+2 (IVS12+2)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Vorgehensweise der VUS Task Force
=================================

Das Konsortium empfiehlt routinemäßig die Erstellung eines Genbefundes über 10 Gene (Stand 8/19), die evidenzbasiert mit Brust- und/oder Eierstockkrebs assoziiert werden konnten: *ATM, BRCA1, BRCA2, BRIP1, CDH1, CHEK2, PALB2, RAD51C, RAD51D* und *TP53* ( <http://www.konsortium-familiaerer-brustkrebs.de/> ).

Zur konsentierten Klassifizierung von neu gemeldeten Sequenzvarianten sowie bei Evidenzen für eine Neubewertung bereits bekannter Varianten finden monatliche Telefonkonferenzen sowie ggf. Arbeitstreffen des „Expertengremiums des Konsortiums zur Bewertung von Varianten mit unklarer Signifikanz (VUS Task-Force) statt. Im Falle einer Neubewertung werden durch die zentrale Datenbank des Konsortiums alle Zentren über diese Neuklassifizierung in Kenntnis gesetzt (Recall-System).

**Es wird weiterhin ausdrücklich darauf hingewiesen, dass sich die Bewertung von Varianten aufgrund neuer Erkenntnisse ändern kann und diese regelmäßig einer Überprüfung durch das Expertengremium unterzogen werden. Ebenso kann sich durch neuere Erkenntnisse die Liste der Kerngene ändern, für die, innerhalb des Deutschen Konsortiums für Brust- und Eierstockkrebs, eine Erstellung eines Befundes empfohlen wird. Dieses, wie auch die Einarbeitung neuerer Erkenntnisse in die hier vorgestellten Klassifizierungsregelungen, werden auf der Internetseite des Deutschen Konsortiums für Familiären Brust- und Eierstockkrebs (** <http://www.konsortium-familiaerer-brustkrebs.de/> **) veröffentlicht werden.**

Klassifizierung von Sequenzvarianten hinsichtlich funktioneller Relevanz
========================================================================

**1. Class1 (funktionell nicht relevant/ohne Funktionsverlust) wenn eines der folgenden Kriterien erfüllt ist:**

1.1   Allelfrequenz der Varianten ≥ 1% (Minor Allele Frequency \[MAF\] ≥ 0,01) in den Großpopulationen z. B. Kaukasier, Afrikaner oder Asiaten. **Cave:** Eine Allelfrequenz ≥ 1% in Subpopulationen mit wenig durchmischtem Genpool (Bsp.: finnische Population, Gründermutationen!) ist nicht ausreichend.

1.2 Varianten mit einer multifaktoriell berechneten Wahrscheinlichkeit von \< 0,001, pathogen zu sein.

**Cave:** Gilt derzeit nur für die Hochrisikogene *BRCA1/2* (exemplarische Berechnung siehe [@R11100909-13] ).

1.3   Varianten in Hochrisikogenen welche in geeigneten Kollektiven von nicht erkrankten Personen ( [Tab. 1](#TB11100909DE-1){ref-type="table"} ) bei mindestens 10 Individuen auftreten.

**2. Class2 (wahrscheinlich ohne Funktionsverlust/funktionell nicht relevant) wenn eines der folgenden Kriterien erfüllt ist:**

2.1   Allelfrequenz der Varianten 0,5 -- 1% (MAF 0,005 -- 0,01) in den Großpopulationen z. B. Kaukasier, Afrikaner oder Asiaten. **Cave:** Eine Allelfrequenz von 0,5 -- 1% in Subpopulationen mit wenig durchmischtem Genpool (Bsp.: finnische Population, Gründermutationen!) ist nicht ausreichend.

2.2   Exonische Varianten (A), die zur Substitution einer Aminosäure (Missense-Varianten) oder kleine In-Frame-Insertionen/Deletionen (Insertionen/Deletionen einer oder weniger Aminosäure\[n\]) führen und deren A-priori-Wahrscheinlichkeit für Pathogenität ≤ 2% ist (A-GVGD Analyse, <http://priors.hci.utah.edu/PRIORS/> ), intronische Varianten (B), die **mehr als − 20 bp, + 10 bp von der Exongrenze entfernt sind** , und synonyme Varianten (C), wenn diese Varianten (A -- C) laut bioinformatischer Vorhersageprogrammen (siehe Anhang A 1) den Spleißmechanismus mit großer Wahrscheinlichkeit nicht verändern. Für die Nicht- *BRCA1/2* -Gene müssen die genannten Varianten in Großpopulationen mit einer Allelfrequenz von 0,001 ≤ MAF \< 0,01 auftreten.

2.3  synonyme Substitutionen oder intronische Varianten, die keine mRNA-Aberrationen in Form von Exon-Deletionen/Duplikationen oder monoallelischer Expression des Wildtyp-Transkripts (wt) in „In-vitro"-Labortests zeigen auch wenn sie laut bioinformatischer Vorhersageprogramme (Programme und Schwellenwerte siehe Anhang A 1) den Spleißmechanismus mit großer Wahrscheinlichkeit verändern.

2.4   Varianten, die im gleichen Gen mit einer eindeutig pathogenen Variante in trans auftreten (Co-Occurrence), wenn gesichert ist, dass ein homozygoter oder compound heterozygoter Genotyp mit einem bekannten klinisch eindeutigen Phänotyp assoziiert ist.

2.5 Varianten mit einer multifaktoriell berechneten Wahrscheinlichkeit, pathogen zu sein, von 0,001 -- 0,049.

**Cave:** Gilt derzeit nur für die Hochrisikogene *BRCA1/2* (exemplarische Berechnung siehe: [@R11100909-13] ).

2.6  Exonische Varianten, die für denselben Aminosäureaustausch wie eine bereits als Class1 bewertete Sequenzvariante codieren, aber auf einen abweichenden Nukleotidaustausch beruhen, wenn sie keine auffällige Spleißvorhersage aufweisen.

2.7   Missense-Varianten, für welche Informationen aus funktionellen Analysen etc. vorliegen, die jedoch für eine multifaktorielle Klassifizierung nicht ausreichen, und durch Expertengremien (z. B. ENIGMA) als Class2 eingestuft werden.

**3.   Class3 (unklare funktionelle Relevanz), wenn eines der folgenden Kriterien erfüllt ist: Varianten, die nicht eindeutig Class1, Class2, Class4, oder Class5 zugeordnet werden können, z. B.:**

3.1   Sonderfälle, die nach den Bewertungskriterien in einer der anderen Klassen eingeordnet werden könnten, aber im Anhang A 5 zu den Besonderheiten der einzelnen Kerngene oder in Tabelle 5, Appendix der *BRCA1/2* classification criteria Version 2.5.1, July 2017 (ENIGMA) aufgeführt sind ( [Tab. 5](#TB11100909DE-5){ref-type="table"} ).

3.2   Varianten mit widersprüchlicher Datenlage bezüglich ihrer Bewertung und noch ausstehenden weiterführenden Untersuchungen.

3.3  Varianten, die bis **− 20 bp, + 10 bp von der Exongrenze entfernt** sind, welche laut bioinformatischer Vorhersageprogrammen (siehe Anhang A 1) den Spleißmechanismus mit großer Wahrscheinlichkeit verändern, sofern eine In-vitro-mRNA-Analyse noch nicht vorliegt (siehe auch [Abb. 2](#FI11100909DE-2){ref-type="fig"} , Schematische Darstellung der Spleißstellen).

3.4 Exon-Duplikationen ohne weiterführende Analysen (z. B. Bruchpunktanalysen, cDNA-Analyse etc.).

3.5 Varianten mit einer multifaktoriell berechneten Wahrscheinlich, pathogen zu sein, von 0,05 -- 0,949.

**Cave:** Gilt derzeit nur für die Hochrisikogene *BRCA1/2* (exemplarische Berechnung siehe [@R11100909-13] ).

**4.    Class4 (wahrscheinlich mit Funktionsverlust/funktionell relevant), wenn eines der folgenden Kriterien erfüllt ist:**

4.1 Varianten mit einer multifaktoriell berechneten Wahrscheinlich von 0,95 -- 0,99, pathogen zu sein.

**Cave:** Gilt derzeit nur für die Hochrisikogene *BRCA1/2* (exemplarische Berechnung siehe Goldgar et al., 2004 [@R11100909-13] ).

4.2    Varianten, welche einen frühzeitigen Stopp der Proteinbiosynthese codieren (Nonsense- oder Frame-Shift-Varianten) und welche nicht den Verlust bekannter klinisch relevanter funktioneller Proteindomänen bedingen, sofern die Stopp-Kodons nicht Downstream der Nonsense-mediated-Decay-(NMD-)relevanten Position, 50 Basenpaare vor dem Ende des vorletzten Exons, liegen.

4.3    Intronische Varianten an Position ± 1,2 oder G \> Nicht-G an letzter Position des Exons: Wenn positive Spleißvorhersage (siehe Anhang A 1) vorliegt und die ersten 6 Basen im Intron nicht GTRRGT lauten, und eine aberrante In-vitro-mRNA-Analyse **noch nicht** vorliegt (d. h. durch Experten-Review \[noch\] nicht bestätigt oder z. B. Exonskipping oder allelspezifische Transkript-Expression, Loss-of-Function als Pathomechanismus nachgewiesen wurde).

**Ausnahmen:**

-   Eine kryptische Spleißstelle (AG/GT) in der Nähe wird aktiviert und das (vorhergesagte) neue Exon wird In Frame gespleißt **(→ Class3)**

-   Das (vorhergesagte) geskippte Exon (bzw. Exons) wird in relevantem Umfang alternativ gespleißt **(→ Class3)** .

-   Das (vorhergesagte) geskippte Exon (bzw. Exons) wird In Frame gespleißt und enthält keine bekannte funktionelle Domäne **(→ Class3)**

4.4    Varianten, welche den gleichen Aminosäureaustausch wie eine bereits als Class5 bewertete, pathogene Missense-Variante codieren, aber durch einen anderen Nukleotid-Austausch bedingt sind, und wenn keine positive Spleißvorhersage (siehe Anhang A 1) vorliegt.

4.5    In-Frame-Deletionen (auch schon bei nur einer Aminosäure), welche zum Verlust einer bereits als Class5 bewerteten Missense-Variante und die zur Unterbrechung bekannter, funktionell wichtiger Domänen führen.

4.6    Große In-Frame-Deletionen, die zur Unterbrechung/Verlust bekannter, funktionell wichtiger Domänen führen.

4.7  Über In-vitro-mRNA-Analysen verifizierte In-Frame-Insertionen, die zur Unterbrechung funktionell wichtiger Domänen führen.

4.8   Varianten, welche zu einer Veränderung des Translationsinitiations-Codon (AUG, Methionin) führen und für die keine Evidenz (z. B. alternatives Start-Codon in unmittelbarer Nähe) für eine alternative Klassifikation vorliegt.

4.9  Varianten, für die Informationen aus funktionellen Analysen, klinische Daten etc. vorliegen, die jedoch für eine multifaktorielle Klassifizierung nicht ausreichen, und die durch Expertengremien (z. B. ENIGMA) als Class4 eingestuft werden.

**5.  Class5 (Funktionsverlust/funktionell relevant) wenn eines der folgenden Kriterien erfüllt ist:**

5.1    Varianten, welche einen frühzeitigen Stopp der Proteinbiosynthese codieren (Nonsense- oder Frame-Shift-Varianten), welche die Expression bekannter klinisch relevanter funktioneller Proteindomänen unterbindet.

5.2 Varianten mit einer multifaktoriell berechneten Wahrscheinlichkeit, pathogen zu sein, von \> 0,99.

**Cave:** Gilt derzeit nur für die Hochrisikogene *BRCA1/2* (exemplarische Berechnung siehe Goldgar et al., 2004 [@R11100909-13] ).

5.3 Spleiß-Varianten, bei denen im Rahmen einer In-vitro-mRNA-Analyse ein Frame-Shift-Effekt nachgewiesen wurde, der zu einem frühzeitigen Stopp der Proteinbiosynthese führt und die Expression bekannter klinisch relevanter funktioneller Proteindomänen unterbindet und für die ein Wildtyp-Transkript des mutierten Allels nicht nachweisbar ist (monoallelische Expression).

5.4 Spleiß-Varianten, bei denen im Rahmen einer In-vitro-mRNA-Analyse eine In-Frame-Deletion/Insertion nachgewiesen wurde, die zur Unterbrechung oder zum Verlust einer bekannten klinisch relevanten funktionellen Domäne oder zu einer funktionell inaktivierenden Änderung der Proteinstruktur führt und für die ein Wildtyp-Transkript des mutierten Allels nicht nachweisbar ist (monoallelische Expression).

5.5  Copy-Number Deletions-Varianten, die in der Unterbrechung oder dem Verlust einer oder mehrerer, bekannter klinisch relevanter funktioneller Domänen beinhaltender Exons resultieren oder in einer Leserasterverschiebung, welche laut Vorhersage zur Inaktivierung bekannter klinisch relevanter funktioneller Domänen führt.

5.6   Copy-Number Duplikations-Varianten jeglicher Größe, die durch Laboranalysen bestätigt wurden, welche ein oder mehrere Exons duplizieren und zu einer Leserasterverschiebung führen, welche laut Vorhersage in einer Inaktivierung bekannter klinisch relevanter funktioneller Domänen resultiert.

Anhang
======

A 1. Spleißvorhersageprogramme und deren Schwellenwerte
=======================================================

Als recht zuverlässig können die Spleißvorhersageprogramme MaxEntScan (MES), Splice Site Finder (SSF) Human Splicing Finder (HSF) betrachtet werden, deren Verwendung daher zur Bewertung von möglichen Effekten auf den Spleißprozess erfolgen sollte. MaxEnt Scan gilt als auffällig ab einer Abweichung von Delta ≥ 15% [@R11100909-14] , Human Splicing Finder ab einem Delta von ≥ 4,1% [@R11100909-10] sowie Splice Site Finder ab einem Delta von ≥ 5% [@R11100909-14] . Bei auffälliger Prädiktion (mindestens 2 der 3 unten genannten Programme) ist zur Abklärung eine mRNA-Analyse notwendig. Voraussetzung ist, dass die physiologische Spleißstelle von der jeweiligen Prädiktionssoftware mit folgenden Schwellenwerten erkannt wird.

Die Schwellenwerte (berechnet für *BRCA1/2* [@R11100909-14] ) liegen bei:

1.  MES \> 3

2.  SSF \> 60

3.  HSF \> 80

Diese Schwellenwerte können in Annäherung auch für die weiteren Gene verwendet werden. Sollten spezifische Schwellenwerte definiert werden, sind diese zu verwenden.

A 2.
====

[Tab. 1](#TB11100909DE-1){ref-type="table"} und [2](#TB11100909DE-2){ref-type="table"} .

A 3. Fließschema zu den Bewertungskriterien
===========================================

[Abb. 1](#FI11100909DE-1){ref-type="fig"} .

A 4. Schematische Darstellung zu Varianten in der Nähe der Spleißstellen
========================================================================

[Abb. 2](#FI11100909DE-2){ref-type="fig"} .

Die Verwendung von Vorhersageprogrammen für mögliche Spleißeffekte ist für alle neuen Veränderungen auch bei Stopp-Mutationen obligat, da beispielsweise „Rescue"-Effekte durch alternative Transkripte auftreten können.

A 5. Besonderheiten der einzelnen Gene
======================================

**Die oben genannten allgemeinen Bewertungskriterien sollen für alle Gene anwendbar sein. Jedoch bestehen Ausnahmen, Abweichungen und Besonderheiten für bestimmte Varianten und Regionen bei den einzelnen Genen, welche aus Gründen der Übersichtlichkeit erst im Folgenden aufgeführt sind.**

A 5.1 *BRCA1/2*
===============

Als Class3 sind zu bewerten: trunkierende *BRCA1* -Mutationen nach der Aminosäureposition 1854 sowie trunkierende *BRCA2* -Varianten nach Aminosäureposition 3308 (hier erfolgt jeweils keine Class1-Bewertung, da strukturelle Veränderungen nicht ausgeschlossen werden können). Ausnahme: Trunkierende Varianten nach dem polymorphen Stopp-Codon p.(Lys3326\*) werden dagegen als verzichtbar/neutral gewertet (Class1) [@R11100909-17] und ENIGMA: p.(Lys3326\*) ist ein häufig nachweisbarer Polymorphismus, welcher nicht mit einem höheren Risiko assoziiert ist, OR 1.3 -- 1.5 abhängig von Brust- oder Ovarialkrebs. Somit werden Varianten, die stromabwärts von p.(Lys3326\*) zu einem Stopp führen, ebenfalls nicht mit einem erhöhten Erkrankungsrisiko assoziiert sein.

Als Class5 in *BRCA1/2* sind zu bewerten: Alle trunkierenden *BRCA1* -Varianten bis zur letzten eindeutig als pathogen beschriebenen Mutation an Aminosäureposition 1853 [@R11100909-18] sowie alle trunkierenden *BRCA2* -Varianten bis Aminosäureposition 3308, c.9924C\>G [@R11100909-19] . Siehe ENIGMA *BRCA1,2* funktionelle Domänen, [Tab. 3](#TB11100909DE-3){ref-type="table"} und [4](#TB11100909DE-4){ref-type="table"} . **Cave:** NMD beachten; die letzten 50 bp im vorletzten Exon sowie Varianten im letzten Exon unterliegen in der Regel nicht dem NMD. Die Aussagen von RNA-Analysen im Blut sind möglicherweise beschränkt, da es sich nicht um das Zielgewebe handelt.

###### 

**Tab. 3**  Auszug aus <https://enigmaconsortium.org/wp-content/uploads/2018/10/ENIGMA_Rules_2017-06-29-v2.5.1.pdf> .

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Table 3: Catalogue of BRCA1 conserved domains/motifs and currently known, clinically important amino acid residues, and relevance for classification of *BRCA1* in-frame and terminal exon sequence variants.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------- -------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  RING                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              1                                                 101                                                L22S (c.65T\>C \[p.Leu22Ser\])\                                                                                                                                                                               Class5 if at least one clinically relevant residue is removed. Otherwise Class3.   <http://www.ncbi.nlm.nih.gov/protein/15988069> ; <http://hci-exlovd.hci.utah.edu> ; multifactorial analysis for H41R (c.122A\>G \[p.His41Arg\]) (Whiley et al., 2014).
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         T37K (c.110C\>A \[p.Thr37Lys\])\                                                                                                                                                                                                                                                                 
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         C39R (c.115T\>C \[p.Cys39Arg\])\                                                                                                                                                                                                                                                                 
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         H41R (c.122A\>G \[p.His41Arg\])\                                                                                                                                                                                                                                                                 
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         C44S (c.130T\>A \[p.Cys44Ser\])\                                                                                                                                                                                                                                                                 
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         C44Y (c.131G\>A \[p.Cys44Tyr\])\                                                                                                                                                                                                                                                                 
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         C61G (c.181T\>G \[p.Cys61Gly\])                                                                                                                                                                                                                                                                  

  NES                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               81                                                99                                                 None reported                                                                                                                                                                                                 Class3                                                                             Domain location description (Rodriguez and Henderson, 2000).

  NLS1                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              503                                               508                                                None reported                                                                                                                                                                                                 Class3                                                                             Domain location description (Chen et al., 1996, Thakur et al., 1997).

  NLS2                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              607                                               614                                                None reported                                                                                                                                                                                                 Class3                                                                             Domain location description (Chen et al., 1996, Thakur et al., 1997).

  NLS3                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              651                                               656                                                None reported                                                                                                                                                                                                 Class3                                                                             Domain location description (Chen et al., 1996).

  COILED-COIL                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       1391                                              1424                                               None reported                                                                                                                                                                                                 Class3                                                                             Domain location description (Hu et al., 2000).

  BRCT DOMAINS                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      1650                                              1863                                               T1685A (c.5053A\>G \[p.Thr1685Ala\])\                                                                                                                                                                         Class5 if at least one clinically relevant residue is removed. Otherwise Class3.   Domain boundaries derived from X-ray crystallography data are aa1646-1863 (1T15, <http://www.ncbi.nlm.nih.gov/Structure/mmdb/mmdbsrv.cgi?uid=27907> ), and ENIGMA functional assay data (Monteiro, unpublished).\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         T1685I (c.5054C\>T \[p.Thr1685Ile\])\                                                                                                                                                                                                                                                            Digestion data indicate aa1860-1863 are dispensable based on susceptibility to digestion (Lee et al., 2010), while pathogenic variant data indicate that 1855-1862 are dispensable (Hayes et al., 2000). Position 1854 is implicated as clinically important by the observation that Y1853X (c.5559C\>G \[p.Tyr1853Ter\]) is a recognised high-risk pathogenic variant.\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         V1688del (c.5062_5064del \[p.Val1688del\])\                                                                                                                                                                                                                                                      These combined data indicate that position 1854 or 1855 is the C-terminal border of the BRCT/BRCA1 relevant for the clinical interpretation of sequence variants in exon 24 of BRCA1. That is, a variant predicted to disrupt expression of protein sequence only downstream\* of position 1855 would not be considered clinically important.
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         R1699W (c.5095C\>T \[p.Arg1699Trp\])\                                                                                                                                                                                                                                                            
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         G1706E (c.5117G\>A \[p.Gly1706Glu\])\                                                                                                                                                                                                                                                            
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         A1708E (c.5123C\>A \[p.Ala1708Glu\])\                                                                                                                                                                                                                                                            
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         S1715R (c.5143A\>C \[p.Ser1715Arg\])\                                                                                                                                                                                                                                                            
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         G1738R (c.5212G\>A \[p.Gly1738Arg\])\                                                                                                                                                                                                                                                            
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         L1764P (c.5291T\>C \[p.Leu1764Pro\])\                                                                                                                                                                                                                                                            
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         I1766S (c.5297T\>G \[p.Ile1766Ser\])\                                                                                                                                                                                                                                                            
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         M1775K (c.5324T\>A \[p.Met1775Lys\])\                                                                                                                                                                                                                                                            
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         M1775R (c.5324T\>G \[p.Met1775Arg\])\                                                                                                                                                                                                                                                            
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         C1787S (c.5359T\>A \[p.Cys1787Ser\])\                                                                                                                                                                                                                                                            
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         G1788V (c.5363G\>T \[p.Gly1788Val\])\                                                                                                                                                                                                                                                            
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         V1838E (c.5513T\>A \[p.Val1838Glu\])                                                                                                                                                                                                                                                             

  ^a^ Missense substitutions in specific functional domains that are designated as Class5 pathogenic based on multifactorial likelihood of the posterior probability of pathogenicity \> 0.99 (listed in <http://hci-exlovd.hci.utah.edu> or individual references), and which have no/little effect on the mRNA transcript profile, *unless* the variant results in an aberrant transcript that encodes a discrete in-frame deletion considered informative for the definition of clinically important domains.\                                                                                                                                                                                                                                                                                                                                                                                                         
  \* Typo was corrected in version 2.5.1.\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                
  Note: The following pathogenic exonic variants known to alter mRNA splicing have been excluded from Table 3 above, as justified below:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  

  **Variant**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       **mRNA Change**                                   **Predicted protein change**                       **Reason for exclusion**                                                                                                                                                                                                                                                                         

  *BRCA1* R1495M (c.4484G\>T \[p.Arg1495Met\])                                                                                                                                                                                                                                                                                                                                                                                                                                                                      r.\[4358_4484del, 4358_4675del\]                  p.(Ala1453Glyfs Ter10) -- predominant transcript   Predominant alternate transcript is out of frame. Loss of function is assumed due to loss of full-length transcript from variant allele (Houdayer et al., 2012, Colombo et al., 2013, Santos et al., 2014).                                                                                      

  *BRCA1* E1559K (c.4675G\>A \[p.Glu1559Lys\])                                                                                                                                                                                                                                                                                                                                                                                                                                                                      r.\[4665_4675del\]                                p.(Gln1366Alafs Ter13)                             Alternate transcript is out-of-frame. Level of full-length transcript not assessed (Wappenschmidt et al., 2012).                                                                                                                                                                                 

  *BRCA1* A1623G (c.4868C\>G \[p.Ala1623Gly\])                                                                                                                                                                                                                                                                                                                                                                                                                                                                      r.\[4868_4986del\]                                p.(Ala1623Aspfs Ter16)                             Alternate transcript is out of frame. Variant allele produces some full-length transcripts (Walker et al., 2010).                                                                                                                                                                                

  *BRCA1* D1692N (c.5074G\>A \[p.Asp1692Asn\])                                                                                                                                                                                                                                                                                                                                                                                                                                                                      r.\[4987_5074del, 5074_5075ins5074+1_5074+153\]   p.(Val1665Serfs Ter8) -- predominant transcript    Predominant alternate transcript, based on minigene assay (Ahlborn et al., 2015), is out of frame.                                                                                                                                                                                               
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

###### 

**Tab. 4**  Auszug aus <https://enigmaconsortium.org/wp-content/uploads/2018/10/ENIGMA_Rules_2017-06-29-v2.5.1.pdf> .

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Table 4: Catalogue of BRCA2 conserved domains/motifs and currently known clinically important amino acid residues, and relevance for classification of *BRCA2* in-frame and terminal exon sequence variants.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ -------------------- ------------------------------ ----------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------- -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  PALB2 Binding                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      10                   40                             None reported                                                                                               Class3                                                                                    Domain location description (Oliver et al., 2009, Xia et al., 2006)

  BRC-1                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              1002                 1036                           None reported                                                                                               Class3                                                                                    <http://www.ncbi.nlm.nih.gov/protein/NP_000050.2>

  BRC-2                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              1212                 1246                           None reported                                                                                               Class3                                                                                    <http://www.ncbi.nlm.nih.gov/protein/NP_000050.2>

  BRC-3                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              1422                 1453                           None reported                                                                                               Class3                                                                                    <http://www.ncbi.nlm.nih.gov/protein/NP_000050.2>

  BRC-4                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              1518                 1549                           None reported                                                                                               Class3                                                                                    <http://www.ncbi.nlm.nih.gov/protein/NP_000050.2>

  BRC-5                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              1665                 1696                           None reported                                                                                               Class3                                                                                    <http://www.ncbi.nlm.nih.gov/protein/NP_000050.2>

  BRC-6                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              1837                 1871                           None reported                                                                                               Class3                                                                                    <http://www.ncbi.nlm.nih.gov/protein/NP_000050.2>

  BRC-7                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              1971                 2005                           None reported                                                                                               Class3                                                                                    <http://www.ncbi.nlm.nih.gov/protein/NP_000050.2>

  BRC-8                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              2051                 2085                           None reported                                                                                               Class3                                                                                    <http://www.ncbi.nlm.nih.gov/protein/NP_000050.2>

  DBD (DNA/DSS1 binding domain -- helical, OB1, OB2, OB3)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            2481                 3186                           W2626C (c.7878G\>C \[p.Trp2626Cys\])\                                                                       Class5 if at least one clinically relevant residue (or all of AA2778-2829) is removed.\   <http://www.ncbi.nlm.nih.gov/protein/NP_000050.2> ; <http://hci-exlovd.hci.utah.edu> .\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         I2627F (c.7879A\>T \[p.Ile2627Phe\])\                                                                       Otherwise Class3.                                                                         Pathogenic variant c.8486G\>A (also recorded as Gln2829Arg) results in a transcript encoding an in-frame exon 19 deletion only (Houdayer et al., 2012), indicating that genetic variation encompassing loss of this entire exon (AA2778-2829) should be considered clinically important. The clinical impact of alteration/deletion of individual amino acids in exon 19 is not yet established.
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         E2663V (c.7988A\>T \[p.Glu2663Val\])\                                                                                                                                                                 
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         T2722R (c.8165C\>G \[p.Thr2722Arg\])\                                                                                                                                                                 
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         D2723G (c.8168A\>G \[p.Asp2723Gly\])\                                                                                                                                                                 
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         D2723H (c.8167G\>C \[p.Asp2723His\])\                                                                                                                                                                 
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         G2748D (c.8243G\>A \[p.Gly2748Asp\])\                                                                                                                                                                 
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         I2778_Q2829del (c.8332_8487del \[p.Ile2778_Gln2829del\])\                                                                                                                                             
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         R3052W (c.9154C\>T \[p.Arg3052Trp\])                                                                                                                                                                  

  NLS1                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               3263                 3269                           None reported                                                                                               Class3                                                                                    Domain local description (Guidugli et al., 2014)

  BRC-9 or TR2                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       3265                 3330                           None reported                                                                                               Class3                                                                                    Note: although amino acids 3270-3305 within this fragment are reported to bind RAD51-DNA filaments (Davies and Pellegrini, 2007), there is no sequence conservation with the BRC repeats located between aa1002 and aa2014. Domain boundaries are derived from x-ray crystallography data are aa3265-3330 (Esashi et al., 2005, Esashi et al., 2007).\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               Case-control and frequency data indicate that BRCA2 c.9976A\>T (p.Lys3326Ter) does not confer a high risk of cancer (OR 1.3--1.5, dependent on breast or ovarian cancer subtype (Meeks et al., 2016), demonstrating that residues at and downstream of 3327 are likely dispensable.\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               Position 3308 is implicated as clinically important by the observation that a nonsense variant c.9924C\>G (p.Tyr3308Ter) is recognized as a high-risk pathogenic variant with known functional relevance (\[Vallee et al., 2016\]; Bayes score 1122 : 1 from a single large kConFab family, Spurdle unpublished data). There is currently no publicly available clinical information to support pathogenicity of nonsense or frameshift variants located between positions 3309 and 3325.\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               These data combined suggest that the C-terminal border of the BRC-9 relevant to the clinical interpretation of sequence variants in exon 27 of BRCA2 lies between 3309 and 3325. That is, a variant predicted to disrupt expression only of protein sequence downstream of position 3325 would be considered unlikely to be clinically important. Further functional and clinical studies are underway to refine risk, if any, for predicted nonsense or frameshift variants downstream of position 3326.

  NLS2                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               3381                 3385                           No                                                                                                          Class3                                                                                    Domain location description (Guidugli et al., 2014).\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               This domain is considered unlikely clinically relevant since it lies downstream of position 3326.

  ^a^ Missense substitutions in denoted functional domains that are designated as Class5 pathogenic based on multifactorial likelihood posterior probability of pathogenicity \> 0.99, and for which there is no/little effect on mRNA transcript profile -- ***unless*** the variant results in an aberrant transcript that encodes a discrete in-frame deletion considered informative to definition of clinically important domains. (Splicing aberrations are reported for *BRCA2* c.7988A\>T \[p.Glu2663Val\] and c.8168A\>G \[p.Asp2723Gly\] (Walker et al., 2010), but these did not lead to complete loss of function of the full length transcript), and missense alterations showed abrogation of functional activity using multiple assays (Walker et al., 2010). An additional conserved region not commonly recognized as a BRCA2 domain/motif is located AA 1110-1183, but no pathogenic missense substitutions have been recorded for this region.\                                                                                                                                                                                                                                                             
  Note -- The following pathogenic exonic variants known to alter mRNA splicing have been excluded from Table 4 above, as justified below:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     

  **Variant**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        **mRNA Change**      **Predicted protein change**   **Reason for exclusion**                                                                                                                                                                              

  *BRCA2* R2659K (c.7976G\>A \[p.Arg2659Lys\])                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       r.\[7806_7976del\]   p.(Ala2603\_ Arg2659del)       Alternate transcript is in-frame but level of full length transcript not assessed (Farrugia et al., 2008)                                                                                             

  *BRCA2* R2659T (c.7976G\>C \[p.Arg2659Thr\])                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       r.\[7806_7976del\]   p.(Ala2603\_ Arg2659del)       Alternate transcript is in-frame but level of full length transcript not assessed (Farrugia et al., 2008)                                                                                             

  *BRCA2* P3039P (c.9117G\>A \[p.Pro3039Pro\])                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       r.\[8954_9117del\]   p.(Val2985 Glyfs\*4)           Allele-specific assay shows out-of-frame transcript (Houdayer et al., 2012)                                                                                                                           
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Weitere Besonderheiten sind im Anhang der Bewertungsrichtlinien des ENIGMA-Konsortiums aufgeführt, die unter folgendem Link abgerufen werden können: <https://enigmaconsortium.org/wp-content/uploads/2018/10/ENIGMA_Rules_2017-06-29-v2.5.1.pdf> , Tabellen 3, 4 und 6 ( [Tab. 3](#TB11100909DE-3){ref-type="table"} bis [5](#TB11100909DE-5){ref-type="table"} ).

A 5.2 *ATM*
===========

Die Bewertungskriterien für *ATM* beruhen auf einer Kombination aus folgenden Kriterien:

-   dem 5-Klassen-IARC-System für die Einschätzung der Pathogenität von *BRCA1* - und *BRCA2* -Varianten,

-   dem 3-Klassen-System zur Einschätzung der Pathogenität von *ATM* -Varianten [@R11100909-20] , welches In-silico-Analysen wie Align-GVGD mitberücksichtigt,

-   den ACMG-Guidelines zur Variantenklassifizierung [@R11100909-3] ,  [@R11100909-21] ,

-   weiteren Literaturstellen: [@R11100909-22] ,  [@R11100909-23] ,  [@R11100909-24] ,  [@R11100909-25] ,  [@R11100909-26] ,  [@R11100909-27] ,  [@R11100909-28] .

Class1:

-   Bei Allelfrequenz ≥ 1% (MAF ≥ 0,01) in den Großpopulationen Kaukasier, Afrikaner oder Asiaten oder Nachweis von homozygoten Variantenträgern in Kontrollpopulationen. Ist dies der Fall, wird die Variante immer als Class1 bewertet. Eine Allelfrequenz ≥ 1% in Subpopulationen mit wenig durchmischtem Genpool (Bsp.: finnische Population, Gründermutationen!) ist nicht ausreichend.

Class2:

-   Bei Allelfrequenz ≥ 0,5--\<1% (MAF ≥ 0,005 -- 0,099) in den Großpopulationen Kaukasier, Afrikaner oder Asiaten wird die Variante immer als Class2 bewertet.

-   Missense-Variante, die gemäß In-silico-Analyse (Align-GVGD, SIFT) mit hoher Wahrscheinlichkeit neutral ist und/oder außerhalb der funktionell kritischen Domäne (FATKIN) liegt.

Class3:

-   Alle Varianten, die nicht in Class1, 2, 4 oder 5 eingeordnet werden können.

Class4:

-   Varianten mit einer In-Frame-Deletion, die innerhalb der funktionell kritischen Domäne (FATKIN) liegt.

-   Missense-Varianten, die innerhalb der funktionell kritischen Domäne (FATKIN) liegen, und gemäß In-silico-Analyse (Align-GVGD, SIFT) mit hoher Wahrscheinlichkeit schädigend und als funktionell inaktiv beschrieben wurden.

Class5:

-   Trunkierende *ATM* -Varianten bis zur FATKIN-Domäne.

-   Missense-Varianten, In-Frame-Deletion oder Spleißveränderungen, die eine Reduktion der ATM-Proteinexpression auf \< 20% für das mutierte Allel verursachen [@R11100909-28] ,  [@R11100909-29] .

-   Varianten, die mit klassischer AT assoziiert sind.

Spleißvarianten: siehe *BRCA1* und *BRCA2* .

Funktionelle Domänen: FATKIN mit FAT; PI3K related Kinase; FATC

[Tab. 6](#TB11100909DE-6){ref-type="table"} .

###### 

**Tab. 6**   *ATM* , funktionelle Domänen und Relevanz für die Interpretation der klinischen Bedeutung von Sequenzvarianten -- Katalog klinisch relevanter funktioneller Domänen und Aminosäuren.

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Region              AA start   AA end   AA alterations with demonstrated clinical importance (AT) characterising known functional domains   References and summary interpretation
  ------------------- ---------- -------- --------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Substrate binding   91         97       None reported                                                                                       Domain location description [@R11100909-30]\
                                                                                                                                              Also contains p53- and BRCA1-binding domain

  NLS                 385        388      None reported                                                                                       Domain location description [@R11100909-28] ,  [@R11100909-31]

  Leucine zipper      1218       1238     None reported                                                                                       Domain location description [@R11100909-25] ,  [@R11100909-28]

  Proline rich        1373       1382     None reported                                                                                       Domain location description [@R11100909-25] ,  [@R11100909-28]

  FATKIN              1893       3056     Yes, e.g.\                                                                                          AA alterations and in-frame deletions [@R11100909-26] ,  [@R11100909-28] ,  [@R11100909-29] ,  [@R11100909-32] ,  [@R11100909-33] ,  [@R11100909-34] ,  [@R11100909-35]\
                                          p.(Val2424Gly)\                                                                                     Domain location description [@R11100909-25] ,  [@R11100909-27] ,  [@R11100909-28] ,  [@R11100909-36] ,  [@R11100909-37]\
                                          p.(2546_2548del), in frame\                                                                         **Domains:**\
                                          p.(Asp2625Glu)\                                                                                     FAT: 1893-2612\
                                          p.(Ala2626Pro)\                                                                                     KIN: 2612-3056 with ATP-binding: 2716-2730, substrate (nibrin and p53) binding: 2682-3012, FATC with TIP60 binding: 3034-3056\
                                          p.(Val2716Ala)\                                                                                     Domain location description
                                          p.(Ser2855_Val2856delinsArgIle)                                                                     
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Weitere Literaturstellen: [@R11100909-22] ,  [@R11100909-23] ,  [@R11100909-24] ,  [@R11100909-25] ,  [@R11100909-26] ,  [@R11100909-28] ,  [@R11100909-33] ,  [@R11100909-35] ,  [@R11100909-38] .

A 5.3 *PALB2*
=============

-   Die Veränderung p.(Leu939Trp) ist als Class2 zu werten [@R11100909-39] .

Weitere Literaturstellen: [@R11100909-35] ,  [@R11100909-38] ,  [@R11100909-40] ,  [@R11100909-41] ,  [@R11100909-42] ,  [@R11100909-43] ,  [@R11100909-44] ,  [@R11100909-45] ,  [@R11100909-46] .

[Tab. 7](#TB11100909DE-7){ref-type="table"} .

###### 

**Tab. 7**   *PALB2* , funktionelle Domänen und Relevanz für die Interpretation der klinischen Bedeutung von Sequenzvarianten -- Katalog klinisch relevanter funktioneller Domänen und Aminosäuren.

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Region                               AA start   AA end   AA alterations with potential clinical importance   References and summary interpretation
  ------------------------------------ ---------- -------- --------------------------------------------------- -----------------------------------------------------------------------------------------------------------------------------------------------
  BRCA1 interaction domain             9          43       Yes, e.g.\                                          Also covers oligomerisation domain/covers coiled-coiled motif\
                                                           p.(Leu35Pro)                                        Domain location description [@R11100909-47] ,  [@R11100909-48] ,  [@R11100909-49] ;\
                                                                                                               Amino acid alteration in VUS and functional analysis [@R11100909-50] .

  DNA-binding site                     1          200      None reported                                       Domain location description [@R11100909-51]

  RAD51 binding site                   101        184      None reported                                       Domain location description [@R11100909-51] ,  [@R11100909-52]

  DNA-binding site                     372        561      None reported                                       Covers also chromatin association motif (ChAM, 395-446)\
                                                                                                               Domain location description [@R11100909-51] ,  [@R11100909-53]

  MRG15 (MORF4L1) interaction domain   611        764      None reported                                       Domain location description [@R11100909-48]

  WD40 repeat                          853        1186     Yes, e.g.\                                          BRCA2 (1019-1098), RAD51C, XRCC3 and/or RAD51 complex formation\
                                                           p.(Thr1030Ile)\                                     Domain location description [@R11100909-51] ,  [@R11100909-52] ,  [@R11100909-54] ,  [@R11100909-55] ,  [@R11100909-56] ,  [@R11100909-57] .\
                                                           p.(Leu1143Pro)                                      Amino acid alterations [@R11100909-48] ,  [@R11100909-54] ,  [@R11100909-58]
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

A 5.4 *CHEK2*
=============

Im Bereich der Exons 11 -- 15 hochhomologe, funktionsinaktive Sequenzbereiche (Pseudogene) auf verschiedenen anderen Chromosomen (2, 7, 10, 13, 15, 16, X, and Y) [@R11100909-59] ,  [@R11100909-60] , die relevante Sequenzbereiche überlagern können \> Long Range PCR der Exons 11 -- 15 und bioinformatische Herausfilterung der Pseudogen-reads falls möglich.

Funktionelle Domänen: SQ/TQ-rich-Domäne\*, Forkhead associated (FHA)\*\*-Domäne, Kinase-Domäne\*\*\*, nukleäres Lokalisationssignal (NLS) [@R11100909-61] ,  [@R11100909-62] ,  [@R11100909-63] .

-   In der SQ/TQ-rich-Domäne sind bisher nur trunkierende Varianten als pathogen eingestuft ( [Tab. 8](#TB11100909DE-8){ref-type="table"} ).

###### 

**Tab. 8**   *CHEK2* , funktionelle Domänen und Relevanz für die Interpretation der klinischen Bedeutung von Sequenzvarianten -- Katalog klinisch relevanter funktioneller Domänen und Aminosäuren.

  Region       AA start     AA end        AA alterations with Potential Clinical Importance                                                                                                                     References and summary interpretation
  ------------ ------------ ------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------
  SQ/TQ-rich   19           69            e.g. c.85C\>T,p.Gln29\*                                                                                                                                               [@R11100909-62] ,  [@R11100909-65]
  FHA          92 \[115\]   205 \[175\]   p.Arg117Gly, p.Arg145Trp, p.Gly167Arg                                                                                                                                 [@R11100909-61] ,  [@R11100909-62] ,  [@R11100909-63]
  Kinase       212          501           c.1040A\>C, p.Asp347Ala \#; c.1100del; c.1164dup; p.Thr476Met, c.1169A\>C, p.Tyr390Ser; c.1183G\>T, p.Val395Phe\#; c.1283C\>T, p.Ser428Phe; c.1427C\>T, p.Thr476Met   [@R11100909-61] ,  [@R11100909-62] , \#ClinVar
  NLS          515          538           e.g. c.1547delC, p.Ser516Leufs\#; c.1555C\>T, p.Arg519Ter\#;                                                                                                          [@R11100909-63] , \#ClinVar

-   Zahlreiche Missense-Varianten in der FHA-Domäne bekannt. **Cave:** Bei Bewertung Flossies-Datenbank berücksichtigen! (z. B. c.470C\>T; p.Ile157Thr: Class2 \[siehe ^§^ Fußnote [Tab. 8](#TB11100909DE-8){ref-type="table"} ) oder mit unklarer klinische Relevanz (z. B. c.434G\>A, p.Arg145Gln; c.422A\>C, p.Lys141Thr).

-   Missense-Varianten in der Kinase-Domäne mit unklarer klinischer Relevanz: z. B. c.1216C\>T, p.Arg406Cys.

-   In der NLS-Domäne sind bisher ebenfalls nur trunkierende Varianten als pathogen eingestuft ( [Tab. 8](#TB11100909DE-8){ref-type="table"} ).

Einen Überblick über identifizierte Mutationen innerhalb des *CHEK2* -Genbereichs findet sich in der Arbeit von Ow et al. [@R11100909-63] . Die Veröffentlichung von Roeb et al., 2012 beinhaltet einen schematischen Überblick der funktionellen Domänen sowie Ergebnisse der funktionellen Analyse von in diesen verschiedenen *CHEK2* -Domänen lokalisierten missense Mutationen [@R11100909-62] .

A 5.5 *TP53*
============

-   IARC *TP53* -Datenbank, funktionelle Analysen von Kato et al., 2003 und Monti et al., 2007, 2011 sind verlässlich [@R11100909-72] ,  [@R11100909-73] ,  [@R11100909-74] ,  [@R11100909-75] ,  [@R11100909-76] ,  [@R11100909-77] .

-   Funktionelle Domänen: Oligomerisierungs-Domäne, Core-Domäne (DNA-Bindung).

-   Möglicher dominant negativer Effekt von Missense-Varianten und Stopp-Varianten, welche die Oligomerisierungsdomäne betreffen.

-   Mosaikmutationen sowie klonale Hämatopoese sind möglich, daher bei NGS-Analysen besonders auf die Variant-Allel-Fraction achten und ggf. weitere Analysen zur Bestätigung von Keimbahnmutationen durchführen.

[Tab. 9](#TB11100909DE-9){ref-type="table"} .

###### 

**Tab. 9**   *p53* , funktionelle Domänen und Relevanz für die Interpretation der klinischen Bedeutung von Sequenzvarianten -- Katalog klinisch relevanter funktioneller Domänen und Aminosäuren.

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Region                                     AA start   AA end   AA alterations with demonstrated clinical importance (including conflicting interpretations of pathogenicity but criteria provided)   References and summary interpretation
  ------------------------------------------ ---------- -------- ------------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------
  Transcription activation                   1          55       p.(Val10Ile)\                                                                                                                         Amino acid alterations (ClinVar)\
                                                                 p.(Val31Ile)\                                                                                                                         Domain location description [@R11100909-78]\
                                                                 p.(Pro47Ser)                                                                                                                          Also binding site for numerous proteins including HDM2 (amino acids 15 -- 29; IARC)

  Proline-rich domain                        61         94       p.(Pro82Leu)\                                                                                                                         Amino acid alterations (ClinVar)\
                                                                 p.(Ala83Val)                                                                                                                          Domain location description [@R11100909-78]

  DNA-binding region                         102        292      p.(Gly105Asp)\                                                                                                                        Amino acid alterations (ClinVar)\
                                                                 p.(Lys120Glu)\                                                                                                                        Domain location description (IARC)\
                                                                 p.(Thr125Met)\                                                                                                                        Also binding site for numerous proteins including 53BP1 (IARC) and RAD51 amino acids 94-160 and 264-315 [@R11100909-79]
                                                                 p.(Ser127Phe)\                                                                                                                        
                                                                 p.(Asn131Tyr)\                                                                                                                        
                                                                 p.(Cys141Tyr)\                                                                                                                        
                                                                 p.(Pro151Ser)\                                                                                                                        
                                                                 p.(Pro151Thr)\                                                                                                                        
                                                                 p.(Pro152Leu)\                                                                                                                        
                                                                 p.(Arg156His)\                                                                                                                        
                                                                 p.(Arg158Cys)\                                                                                                                        
                                                                 p.(Arg158His)\                                                                                                                        
                                                                 p.(Tyr163Asp)\                                                                                                                        
                                                                 p.(Tyr163Cys)\                                                                                                                        
                                                                 p.(Arg175Leu)\                                                                                                                        
                                                                 p.(Arg175His)\                                                                                                                        
                                                                 p.(Cys176Tyr)\                                                                                                                        
                                                                 p.(His179Tyr)\                                                                                                                        
                                                                 p.(Arg181Cys)\                                                                                                                        
                                                                 p.(Arg181His)\                                                                                                                        
                                                                 p.(Ala189Val)\                                                                                                                        
                                                                 p.(His193Arg)\                                                                                                                        
                                                                 p.(His193Leu)\                                                                                                                        
                                                                 p.(Leu194Phe)\                                                                                                                        
                                                                 p.(Ile195Thr)\                                                                                                                        
                                                                 p.(Arg213Gln)\                                                                                                                        
                                                                 p.(Val.216Met)\                                                                                                                       
                                                                 p.(Tyr220Cys)\                                                                                                                        
                                                                 p.(Tyr220Ser)\                                                                                                                        
                                                                 p.(Ile232Thr)\                                                                                                                        
                                                                 p.(Tyr234Cys)\                                                                                                                        
                                                                 p.(Asn235Ser)\                                                                                                                        
                                                                 p.(Tyr236Asp)\                                                                                                                        
                                                                 p.(Met237Val)\                                                                                                                        
                                                                 p.(Met237Ile)\                                                                                                                        
                                                                 p.(Cys238Tyr)\                                                                                                                        
                                                                 p.(Ser241Phe)\                                                                                                                        
                                                                 p.(Cys242Tyr)\                                                                                                                        
                                                                 p.(Gly245Asp)\                                                                                                                        
                                                                 p.(Gly245Ser)\                                                                                                                        
                                                                 p.(Gly245Cys)\                                                                                                                        
                                                                 p.(Met246Val)\                                                                                                                        
                                                                 p.(Met246Leu)\                                                                                                                        
                                                                 p.(Met246Arg)\                                                                                                                        
                                                                 p.(Arg248Gln)\                                                                                                                        
                                                                 p.(Arg248Trp)\                                                                                                                        
                                                                 p.(Ile251Leu)\                                                                                                                        
                                                                 p.(Ile251Ser)\                                                                                                                        
                                                                 p.(Thr256Ala)\                                                                                                                        
                                                                 p.(Leu257Arg)\                                                                                                                        
                                                                 p.(Glu258Lys)\                                                                                                                        
                                                                 p.(Arg267Trp)\                                                                                                                        
                                                                 p.(Arg267Gln)\                                                                                                                        
                                                                 p.(Val272Leu)\                                                                                                                        
                                                                 p.(Arg273Hisv\                                                                                                                        
                                                                 p.(Arg273Cys)\                                                                                                                        
                                                                 p.(Cys275Tyr)\                                                                                                                        
                                                                 p.(Cys277Tyr)\                                                                                                                        
                                                                 p.(Arg280Thr)\                                                                                                                        
                                                                 p.(Asp281Val)\                                                                                                                        
                                                                 p.(Asp281Gly)\                                                                                                                        
                                                                 p.(Arg282Gly)\                                                                                                                        
                                                                 p.(Arg282Leu)\                                                                                                                        
                                                                 p.(Arg282Trp)\                                                                                                                        
                                                                 p.(Arg283His)\                                                                                                                        
                                                                 p.(Arg283Lys)\                                                                                                                        
                                                                 p.(Glu286Lys)                                                                                                                         

  Oligomerisation region                     325        356      p.(Gly325Val)\                                                                                                                        Amino acid alterations (ClinVar)\
                                                                 p.(Arg337Leu)\                                                                                                                        Domain location description (IARC)\
                                                                 p.(Arg337Cys)\                                                                                                                        Also binding site for numerous proteins\
                                                                 p.(Glu339Lys)\                                                                                                                        Covering main nuclear localisation signal (amino acids 316-322) [@R11100909-80] ,  [@R11100909-81]
                                                                 p.(Arg342Pro)                                                                                                                         

  Basic (repression of DNA-binding region)   369        388      None reported                                                                                                                         Domain location description (IARC)\
                                                                                                                                                                                                       Also binding site for numerous proteins including RAD54 [@R11100909-82]
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

A 5.6 *RAD51D*
==============

Funktionelle Domänen: N-terminale Domäne und „ATP binding domain" mit den hochkonservierten Walker A und B Motiven [@R11100909-83] ,  [@R11100909-84] ,  [@R11100909-85] .

[Tab. 10](#TB11100909DE-10){ref-type="table"} .

###### 

**Tab. 10**   *RAD51D* , funktionelle Domänen und Relevanz für die Interpretation der klinischen Bedeutung von Sequenzvarianten -- Katalog klinisch relevanter funktioneller Domänen und Aminosäuren.

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Region                                                AA start   AA end   AA alterations with demonstrated clinical importance (including conflicting interpretations of pathogenicity)   References and summary interpretation
  ----------------------------------------------------- ---------- -------- --------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------
  N-terminal region                                     1          83       None reported                                                                                                   N-terminal domain required for ssDNA-specific binding function [@R11100909-86]

  Linker                                                60         78       None reported                                                                                                   Proper interaction with RAD51C and XRCC2 [@R11100909-85]

  ATPase domain and RAD51B, RAD51C, and XRCC2 binding   99         274      p.(G112A) (disrupts binding of RAD51D to RAD51C [@R11100909-87] )\                                              ATPase, AAA+ type\
                                                                            p.(S207L) (disrupts RAD51D-XRCC2 interaction [@R11100909-85] )\                                                 Walker A and B motifs crucial for HR. These motifs are also implicated in binding to RAD51C and XRCC2.
                                                                            p.(A210V) (predicted to be potentially pathogenic [@R11100909-88] ,  [@R11100909-89] )\                         
                                                                            p.(R266C) [@R11100909-90] , Meindl et al. (unpublished)                                                         
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Weitere Literaturstellen: [@R11100909-91] ,  [@R11100909-92] ,  [@R11100909-93] ,  [@R11100909-94]

A 5.7 *RAD51C*
==============

Literatur: [@R11100909-91] ,  [@R11100909-95]  --  [@R11100909-101]

Funktionelle Domänen: „DNA repair/recombination protein RecA-like ATP binding Domain"

[Tab. 11](#TB11100909DE-11){ref-type="table"} .

###### 

**Tab. 11**   *RAD51C* , funktionelle Domänen und Relevanz für die Interpretation der klinischen Bedeutung von Sequenzvarianten -- Katalog klinisch relevanter funktioneller Domänen und Aminosäuren.

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Region                                                AA start   AA end   AA alterations with demonstrated clinical importance (including conflicting interpretations of pathogenicity)   References and summary interpretation
  ----------------------------------------------------- ---------- -------- --------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  N-terminal region                                     1          66       None reported                                                                                                   Homology-derived putative DNA-binding domain [@R11100909-91]

  ATPase domain and RAD51B, XRCC3, and RAD51D binding   79         376      p.(Gly125Val)\                                                                                                  Amino acid alterations and functional consequences [@R11100909-95] ,  [@R11100909-96] ,  [@R11100909-97] ,  [@R11100909-98] Domain location description [@R11100909-91] ATPase domain includes Walker A nucleotide binding motif (amino acids 125 -- 132) and Walker B nucleotide binding motif (amino acids 238 -- 242) [@R11100909-91] ,  [@R11100909-99]
                                                                            p.(Cys135Tyr)\                                                                                                  
                                                                            p.(Leu138Phe)\                                                                                                  
                                                                            p.(Gly153Asp)\                                                                                                  
                                                                            p.(Asp159Asn)\                                                                                                  
                                                                            p.(Val169Ala)\                                                                                                  
                                                                            p.(Leu219Ser)\                                                                                                  
                                                                            p.(Arg258His)\                                                                                                  
                                                                            p.(Gly264Ser)                                                                                                   

  Nuclear localisation signal                           366        370      None reported                                                                                                   Domain location description [@R11100909-99]
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

A 5.8 *BRIP1*
=============

[Tab. 12](#TB11100909DE-12){ref-type="table"} .

###### 

**Tab. 12**   *BRIP1* , funktionelle Domänen und Relevanz für die Interpretation der klinischen Bedeutung von Sequenzvarianten -- Katalog klinisch relevanter funktioneller Domänen und Aminosäuren.

  Region                                   AA start   AA end   AA alterations with demonstrated clinical importance (including conflicting interpretations of pathogenicity)   References and summary interpretation
  ---------------------------------------- ---------- -------- --------------------------------------------------------------------------------------------------------------- ----------------------------------------------
  DEAD/DEAH box helicase domain            17         441                                                                                                                      Domain location description [@R11100909-102]
  Helicase superfamily c-terminal domain   697        851                                                                                                                      Domain location description [@R11100909-102]
  The BRCA1 interacting region of BRIP1    976        1006     Phosphorylation of FANCJ at Ser-990 is important for its interaction with BRCA1                                 [@R11100909-103]
  MLH1 interaction                                             Lysines 141 and 142 are required for direct interaction of FANCJ with MLH1                                      [@R11100909-104]
  Nuclear localisation signal              158        175      None reported                                                                                                   Domain location description [@R11100909-102]

Weitere Literaturstellen: [@R11100909-1] ,  [@R11100909-102] ,  [@R11100909-105] ,  [@R11100909-106] ,  [@R11100909-107] ,  [@R11100909-108] ,  [@R11100909-109] ,  [@R11100909-110]

A 5.9 CDH1
==========

Literatur:

Vorwiegend auf die Molekulargenetik eingehend: [@R11100909-111]

Review funktionelle Analysen: [@R11100909-112]

Review des HDGC-Konsortiums: [@R11100909-113]

Review zu lobulärem Brustkrebs: [@R11100909-114]

Verteilung von pathogen Varianten über den *CDH1* -Locus [@R11100909-111]

Bisher bekannte pathogene CDH1-Varianten sind über den gesamten Locus verteilt und es kann daher keine klinisch relevante funktionelle Protein-Domäne definiert werden. Letzte bekannte trunkierende pathogene Variante im letzten Exon ist c.2506G\>T (p.Glu836\*) [@R11100909-115] . Alle trunkierenden Varianten Upstream müssten daher mindestens als Klasse 4 eingestuft werden.

Der Vorschlag des ClinGen-Konsortiums, abweichend von IARC Guidelines, Varianten mit einer MAF \> 0,2% als Klasse 1 nach ACMG zu klassifizieren, ist derzeit Gegenstand der Diskussion.

CDH1 Rule Specifications for the ACMG/AMP Variant Curation Guidelines ClinGen ( <https://www.clinicalgenome.org/site/assets/files/8816/clingen_cdh1_acmg_specifications_v1.pdf> ).
